

SAFEGUARD SCIENTIFICS INC

Form 10-Q

November 05, 2007

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 10-Q**  
**Quarterly Report Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**  
**For Quarter Ended September 30, 2007**

**Commission File Number 1-5620**  
**SAFEGUARD SCIENTIFICS, INC.**  
**(Exact name of registrant as specified in its charter)**

**Pennsylvania**  
*(State or other jurisdiction of  
incorporation or organization)*

**23-1609753**  
*(I.R.S. Employer ID No.)*

**435 Devon Park Drive**  
**Building 800**  
**Wayne, PA**  
*(Address of principal executive offices)*

**19087**  
*(Zip Code)*

**(610) 293-0600**

**Registrant's telephone number, including area code**

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).

Yes  No

**Number of shares outstanding as of November 2, 2007**  
**Common Stock 121,029,122**

**SAFEGUARD SCIENTIFICS, INC.  
QUARTERLY REPORT ON FORM 10-Q  
INDEX**

	<b>Page</b>
<b>PART I FINANCIAL INFORMATION</b>	
Item 1 - Financial Statements:	
<u>Consolidated Balance Sheets September 30, 2007 (unaudited) and December 31, 2006</u>	3
<u>Consolidated Statements of Operations (unaudited) Three and Nine Months Ended September 30, 2007 and 2006</u>	4
<u>Consolidated Statements of Cash Flows (unaudited) Nine Months Ended September 30, 2007 and 2006</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
<u>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	24
<u>Item 3 - Quantitative and Qualitative Disclosures About Market Risk</u>	49
<u>Item 4 - Controls and Procedures</u>	49
<b>PART II OTHER INFORMATION</b>	
<u>Item 1 - Legal Proceedings</u>	51
<u>Item 1A Risk Factors</u>	51
<u>Item 6 Exhibits</u>	53
<u>Signatures</u>	54
<u>Letter Agreement, Brian J. Sisko</u>	
<u>Stock Option Grant Certificates issued to Brian J. Sisko</u>	
<u>Certification of Peter J. Boni</u>	
<u>Certification of Raymond J. Land</u>	
<u>Certification of Peter J. Boni, pursuant to Section 906</u>	
<u>Certification of Raymond J. Land, pursuant to Section 906</u>	

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.  
CONSOLIDATED BALANCE SHEETS**

	<b>September 30, 2007</b>	<b>December 31, 2006</b>
	<b>(In thousands, except per share data)</b>	
	<b>(unaudited)</b>	
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$ 111,784	\$ 67,012
Marketable securities	542	94,155
Restricted marketable securities	3,861	3,869
Accounts receivable, less allowances (\$2,271 - 2007; \$1,713 - 2006)	37,573	33,167
Prepaid expenses and other current assets	6,516	5,080
Current assets of discontinued operations		11,703
Total current assets	160,276	214,986
Property and equipment, net	35,383	34,209
Ownership interests in and advances to companies	91,445	54,548
Long-term marketable securities		487
Long-term restricted marketable securities	1,946	5,737
Intangible assets, net	10,409	11,984
Goodwill	77,024	80,418
Cash held in escrow	22,439	19,398
Other	3,816	3,764
Non-current assets of discontinued operations		17,850
Total Assets	\$ 402,738	\$ 443,381
 <b>LIABILITIES AND SHAREHOLDERS EQUITY</b>		
Current Liabilities:		
Current portion of credit line borrowings	\$ 39,398	\$ 25,014
Current maturities of long-term debt	3,531	3,192
Accounts payable	6,074	10,581
Accrued compensation and benefits	12,522	13,432
Accrued expenses and other current liabilities	18,628	18,733
Deferred revenue	4,788	3,560
Current liabilities of discontinued operations		3,465
Total current liabilities	84,941	77,977
Long-term debt	4,832	4,010
Other long-term liabilities	9,850	10,319
Convertible senior debentures	129,000	129,000
Deferred taxes	1,026	1,026
Minority interest	4,315	5,491
Non-current liabilities of discontinued operations		1,656

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Commitments and contingencies		
Redeemable subsidiary stock-based compensation	138	2,021
Shareholders' Equity:		
Preferred stock, \$0.10 par value; 1,000 shares authorized		
Common stock, \$0.10 par value; 500,000 shares authorized; 121,029 and 120,419 shares issued and outstanding in 2007 and 2006, respectively	12,103	12,042
Additional paid-in capital	756,851	750,361
Accumulated deficit	(600,338)	(551,058)
Accumulated other comprehensive income	20	536
Total shareholders' equity	168,636	211,881
Total Liabilities and Shareholders' Equity	\$ 402,738	\$ 443,381

See Notes to Consolidated Financial Statements.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2007	2006	2007	2006
	(in thousands, except per share data) (unaudited)			
Revenue	\$ 45,747	\$ 41,837	\$ 128,988	\$ 118,429
Operating Expenses:				
Cost of sales	31,409	29,819	91,702	86,594
Selling, general and administrative	24,606	23,145	71,909	68,192
Research and development	495	616	1,876	1,697
Amortization of intangibles	526	646	1,575	1,893
Goodwill impairment	5,438		5,438	
Total operating expenses	62,474	54,226	172,500	158,376
Operating loss	(16,727)	(12,389)	(43,512)	(39,947)
Other income (loss), net	(4,248)	3,076	(4,894)	4,972
Interest income	1,763	1,398	6,091	4,513
Interest expense	(1,965)	(1,723)	(5,650)	(4,918)
Equity loss	(4,169)	(1,910)	(9,348)	(2,180)
Minority interest	1,224	1,432	4,005	4,684
Net loss from continuing operations before income taxes	(24,122)	(10,116)	(53,308)	(32,876)
Income tax (expense) benefit		(2)	696	1,273
Net loss from continuing operations	(24,122)	(10,118)	(52,612)	(31,603)
Income from discontinued operations, net of tax	72	511	3,332	6,309
Net loss	\$ (24,050)	\$ (9,607)	\$ (49,280)	\$ (25,294)
Basic and Diluted Loss Per Share:				
Net loss from continuing operations	\$ (0.20)	\$ (0.08)	\$ (0.43)	\$ (0.26)
Net income from discontinued operations			0.03	0.05
Net loss per share	\$ (0.20)	\$ (0.08)	\$ (0.40)	\$ (0.21)
Shares used in computing basic and diluted loss per share	122,440	121,541	122,299	121,441

See Notes to Consolidated Financial Statements.

Table of Contents

**SAFEGUARD SCIENTIFICS, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

	<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(in thousands) (unaudited)</b>	
<b>Cash Flows from Operating Activities:</b>		
Cash flows from operating activities of continuing operations	\$ (33,036)	\$ (20,138)
Cash flows from operating activities of discontinued operations	883	2,247
Net cash used in operating activities	(32,153)	(17,891)
<b>Cash Flows from Investing Activities:</b>		
Proceeds from sales of available-for-sale and trading securities		348
Proceeds from sales of and distributions from companies and funds	2,359	1,530
Advances to companies	(453)	
Acquisitions of ownership interests in companies and funds, net of cash acquired	(55,788)	(43,253)
(Recovery costs) repayments of note receivable related party		(415)
Increase in marketable securities	(111,268)	(62,016)
Decrease in marketable securities	204,880	64,370
Proceeds from the sale of property and equipment	24	256
Capital expenditures	(7,090)	(11,061)
Capitalized software costs	(156)	(171)
Proceeds from sale of discontinued operations, net	29,967	6,154
Other, net		539
Cash flows from investing activities of discontinued operations	(362)	(6,791)
Net cash provided by (used in) investing activities	62,113	(50,510)
<b>Cash Flows from Financing Activities:</b>		
Repurchase of convertible senior debentures		(16,215)
Borrowings on revolving credit facilities	117,309	102,911
Repayments on revolving credit facilities	(102,925)	(91,182)
Borrowings on term debt	3,944	2,291
Repayments on term debt	(2,887)	(3,272)
Issuance of Company common stock, net	586	356
Issuance of subsidiary common stock, net	372	50
Offering costs on issuance of subsidiary common stock		(70)
Cash flows from financing activities of discontinued operations	(230)	127
Net cash provided by (used in) financing activities	16,169	(5,004)
Net Increase (Decrease) in Cash and Cash Equivalents	46,129	(73,405)

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Changes in cash and cash equivalents from Pacific Title and Art Studio and Mantas included in assets of discontinued operations	(1,357)	(1,091)
Cash and Cash Equivalents at beginning of period	67,012	122,069
Cash and Cash Equivalents at end of period	\$ 111,784	\$ 47,573

See Notes to Consolidated Financial Statements.

5

---



**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
SEPTEMBER 30, 2007**

**1. GENERAL**

The accompanying unaudited interim Consolidated Financial Statements were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statements rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and included together with the Company's Consolidated Financial Statements and Notes thereto included in the Company's 2006 Annual Report on Form 10-K.

**2. BASIS OF PRESENTATION**

The Consolidated Financial Statements include the accounts of the Company and all subsidiaries in which it directly or indirectly owns more than 50% of the outstanding voting securities.

The Company's Consolidated Statements of Operations and Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2007 and 2006 and Consolidated Balance Sheets at September 30, 2007 and December 31, 2006 include the following subsidiaries in continuing operations:

Acsis, Inc. ( Acsis )

Alliance Consulting Group Associates, Inc. ( Alliance Consulting )

Clariant, Inc. ( Clariant )

Laureate Pharma, Inc. ( Laureate Pharma )

Alliance Consulting operates on a 52 or 53-week fiscal year, ending on the Saturday closest to the end of the fiscal period. The Company and all other subsidiaries operate on a calendar year. Alliance Consulting's third quarter ended on September 29, 2007 and September 30, 2006, respectively, each a period of 13 weeks and year-to-date a period of 39 weeks.

During 2007 and 2006, certain consolidated companies, or components thereof, were sold. See Note 3 for discontinued operations treatment of Pacific Title & Art Studio, Inc. ( Pacific Title ), Clariant's technology group business, Mantas, Inc. ( Mantas ) and Alliance Consulting's Southwest region.

**3. DISCONTINUED OPERATIONS**

***Pacific Title and Art Studio***

In March 2007, the Company sold Pacific Title for net cash proceeds of approximately \$21.9 million, including \$2.3 million cash held in escrow. As a result of the sale, the Company recorded a pre-tax gain of \$2.7 million in the first quarter of 2007. Pacific Title is reported in discontinued operations for all periods presented.

***Clariant Technology Group***

In March 2007, Clariant sold its technology group business (which developed, manufactured and marketed the ACIS Automated Image Analysis System) and related intellectual property to Carl Zeiss MicroImaging, Inc. (the ACIS Sale ) for net cash proceeds of \$10.3 million (excluding \$1.5 million in contingent purchase price). As a result of the sale, Clariant recorded a pre-tax gain of \$3.6 million in the first quarter of 2007. The technology group business is reported in discontinued operations for all periods presented. Goodwill of \$2.1 million related to the technology group business was included in discontinued operations.

Table of Contents

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

***Mantas***

In October 2006, the Company sold its interest in Mantas for net cash proceeds of approximately \$112.8 million, including \$19.3 million cash held in escrow. The Company recorded a pre-tax gain of \$83.9 million in the fourth quarter of 2006. Mantas is reported in discontinued operations for the three and nine months ended September 30, 2006. Mantas sold its telecommunications business and certain related assets and liabilities in the first quarter of 2006 for \$2.1 million in cash. As a result of the sale, Mantas recorded a gain of \$1.9 million in the first quarter of 2006, which is also reported in discontinued operations.

***Alliance Consulting Southwest Region***

Alliance Consulting sold its Southwest region in May 2006 for proceeds of \$4.5 million, including cash of \$3.0 million and stock of the acquiror of \$1.5 million, which was subsequently sold. As a result of the sale, Alliance Consulting recorded a gain of \$1.6 million in the second quarter of 2006. Alliance Consulting's Southwest region is reported in discontinued operations for the three and nine months ended September 30, 2006.

Results of all discontinued operations were as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(in thousands) (unaudited)</b>			
Revenue	\$	\$ 16,555	\$ 7,326	\$ 55,765
Operating expenses		(16,445)	(8,098)	(53,186)
Other		(25)	(103)	(571)
Net income (loss) before income taxes and minority interest		85	(875)	2,008
Income tax (expense) benefit		(187)	8	(361)
Income (loss) from operations		(102)	(867)	1,647
Gain on disposal, net of tax	134	256	6,426	3,665
Minority interest	(62)	357	(2,227)	997
Income from discontinued operations, net of tax	\$ 72	\$ 511	\$ 3,332	\$ 6,309

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

The assets and liabilities of the discontinued operations were as follows:

	<b>December 31, 2006 (in thousands)</b>
Cash	\$ 4,239
Accounts receivable, less allowances	5,393
Inventory	1,525
Other current assets	546
<b>Total current assets</b>	<b>11,703</b>
Property and equipment, net	10,680
Intangibles	4,442
Goodwill	2,080
Other assets	648
<b>Total Assets</b>	<b>\$ 29,553</b>
Current debt	\$ 746
Accounts payable	530
Accrued expenses	1,499
Deferred revenue	690
<b>Total current liabilities</b>	<b>3,465</b>
Long-term debt	1,057
Other long-term liabilities	599
<b>Total Liabilities</b>	<b>\$ 5,121</b>
Carrying value	\$ 24,432

**4. MARKETABLE SECURITIES**

Marketable securities included the following:

	<b>Current</b>		<b>Non-Current</b>	
	<b>September 30, 2007</b>	<b>December 31, 2006</b>	<b>September 30, 2007</b>	<b>December 31, 2006</b>
	<b>(in thousands)</b>			
	<b>(unaudited)</b>		<b>(unaudited)</b>	
Held-to-maturity:				
Commercial paper	\$ 542	\$ 94,155	\$	\$
Restricted U.S. Treasury securities	3,861	3,869	1,946	5,737

	4,403	98,024	1,946	5,737
Available-for-sale: Equity securities				487
	\$ 4,403	\$ 98,024	\$ 1,946	\$ 6,224

As of September 30, 2007, the contractual maturities of securities were as follows:

	<b>Years to Maturity (in thousands) (unaudited)</b>			
	<b>Less Than One Year</b>	<b>One to Five Years</b>	<b>No Single Maturity Date</b>	<b>Total</b>
Held-to-maturity	\$ 4,403	\$ 1,946	\$	\$ 6,349

Table of Contents

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

During the nine months ended September 30, 2007, the Company's investment in available-for-sale securities was written-off due to the cancellation of the underlying securities in connection with a bankruptcy liquidation. The change is reflected in Accumulated Other Comprehensive Income on the Consolidated Balance Sheets.

**5. GOODWILL AND OTHER INTANGIBLE ASSETS**

The following is a summary of changes in the carrying amount of goodwill by segment:

	Alliance Consulting	Clariant	Acsis	Total
	<b>(in thousands)</b>			
	<b>(unaudited)</b>			
Balance at December 31, 2006	\$ 56,155	\$ 12,729	\$ 11,534	\$ 80,418
Purchase price adjustments	2,044			2,044
Impairment	(5,438)			(5,438)
Balance at September 30, 2007	\$ 52,761	\$ 12,729	\$ 11,534	\$ 77,024

In July 2006, Alliance Consulting acquired Fusion Technologies for \$5.4 million in cash. Based on achievement of earnings targets by the Fusion business in the post-acquisition period, additional purchase price consideration of \$2.0 million was recorded by Alliance in the nine months ended September 30, 2007, comprised of \$1.7 million in cash and \$0.3 million in Alliance Consulting common stock.

In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets", the Company conducts a review for impairment of goodwill at least annually as of December 1<sup>st</sup> and on an interim basis whenever events or changes in circumstances would more likely than not reduce the fair value of a reporting unit below its carrying value. The Company tests for impairment at a level referred to as a reporting unit (same as or one level below an operating segment as defined in SFAS No. 131, "Disclosures About Segments of an Enterprise and Related Information").

In the third quarter of 2007, the Company conducted a goodwill impairment review related to its Alliance Consulting segment, due to underperformance relative to historical and expected operating results. The Company engaged an outside valuation firm to assist in determining the fair value of Alliance Consulting using valuation methods which included discounted cash flows and revenue and acquisition multiples for comparable public companies. The Company determined that the carrying value of Alliance Consulting exceeded its fair value, indicating a potential impairment of goodwill. The Company then estimated the implied fair value of the Alliance Consulting goodwill. The excess of the carrying value of goodwill over the implied fair value of goodwill was \$5.4 million, which amount was recognized as an impairment loss within Goodwill impairment in the Consolidated Statements of Operations.

Intangible assets with definite useful lives are amortized over their respective estimated useful lives to their estimated residual values. The following table provides a summary of the Company's intangible assets with definite and indefinite useful lives:

	<b>September 30, 2007</b>			
	<b>Amortization Period</b>	<b>Gross Carrying Value</b>	<b>Accumulated Amortization</b>	<b>Net</b>
		<b>(In thousands)</b>		
		<b>(unaudited)</b>		
Customer-related	7 - 10 years	\$ 9,721	\$ 3,562	\$ 6,159

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Technology-related	3 years	1,376	841	535
Process-related	3 years	1,363	1,326	37
Tradenames	20 years	1,222	111	1,111
		13,682	5,840	7,842
Tradenames	Indefinite	2,567		2,567
Total		\$ 16,249	\$ 5,840	\$ 10,409

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

	Amortization Period	December 31, 2006		Net
		Gross Carrying Value	Accumulated Amortization	
(In thousands)				
Customer-related	7 - 10 years	\$ 9,721	\$ 2,719	\$ 7,002
Technology-related	3 years	1,376	496	880
Process-related	3 years	1,363	984	379
Tradenames	20 years	1,222	66	1,156
		13,682	4,265	9,417
Tradenames	Indefinite	2,567		2,567
Total		\$ 16,249	\$ 4,265	\$ 11,984

Amortization expense related to intangible assets was \$0.5 million and \$1.6 million for the three and nine months ended September 30, 2007, and \$0.6 million and \$1.9 million for the three and nine months ended September 30, 2006, respectively. The following table provides estimated future amortization expense related to intangible assets:

	Total (In thousands) (unaudited)
Remainder of 2007	\$ 451
2008	1,610
2009	1,165
2010	670
2011 and thereafter	3,946
	\$ 7,842

**6. RECENT ACCOUNTING PRONOUNCEMENTS**

In June 2007, the AICPA issued Statement of Position 07-1, Clarification of the Scope of the Audit and Accounting Guide: Investment Companies and Accounting by Parent Companies and Equity Method Investors for Investments in Investment Companies (SOP 07-1). SOP 07-1 provides guidance for determining whether an entity is within the scope of the AICPA Audit and Accounting Guide: Investment Companies (the Guide). SOP 07-1 amends the Guide to include criteria for determining whether an entity is an investment company for accounting purposes and is therefore within the Guide's scope. Those criteria include a definition of an investment company and factors to consider in determining whether an entity meets that definition. Entities meeting the definition of an investment company, as well as entities regulated by the Investment Company Act of 1940 or similar requirements, are required

to follow the Guide's specialized accounting guidance. In October 2007, the Financial Accounting Standards Board ( FASB ) indefinitely delayed the effective date of SOP 07-01.

In February 2007, the FASB issued SFAS No. 159, Fair Value Option for Financial Assets and Liabilities ( SFAS No. 159 ). SFAS No. 159 allows companies to choose, at specific election dates, to measure eligible financial assets and liabilities that are not otherwise required to be measured at fair value, at fair value. Under SFAS No. 159, companies would report unrealized gains and losses for which the fair value option has been elected in earnings at each subsequent reporting date, and recognize up-front costs and fees related to those items in earnings as incurred. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating the impact of adopting SFAS No. 159.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements ( SFAS No. 157 ). SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company does not expect the adoption of SFAS No. 157 to have a material impact on its financial statements.



**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes an interpretation of FASB Statement No. 109 ( FIN 48 ). FIN 48 defines the threshold for recognizing the benefits of tax return positions in the financial statements as more-likely-than-not to be sustained upon examination by the applicable taxing authority. FIN 48 also includes guidance concerning accounting for income tax uncertainties in interim periods and increases the level of disclosures associated with any recorded income tax uncertainties. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company adopted FIN 48 effective January 1, 2007. See Note 11.

**7. COMPREHENSIVE LOSS**

Comprehensive loss is the change in equity of a business enterprise from transactions and other events and circumstances from non-owner sources. Excluding net loss, the Company's sources of comprehensive loss are from net unrealized appreciation (depreciation) on its holdings classified as available-for-sale and foreign currency translation adjustments.

The following summarizes the components of comprehensive loss:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>			
	<b>(unaudited)</b>			
Net loss from continuing operations	\$ (24,122)	\$ (10,118)	\$ (52,612)	\$ (31,603)
Other comprehensive income (loss):				
Foreign currency translation adjustments	16	(18)	(29)	69
Unrealized holding losses on available-for-sale securities		(201)	(487)	(2,383)
Other comprehensive income (loss) from continuing operations	16	(219)	(516)	(2,314)
Comprehensive loss from continuing operations	(24,106)	(10,337)	(53,128)	(33,917)
Net income from discontinued operations	72	511	3,332	6,309
Comprehensive loss	\$ (24,034)	\$ (9,826)	\$ (49,796)	\$ (27,608)

**8. LONG-TERM DEBT AND CREDIT ARRANGEMENTS**

Consolidated long-term debt consisted of the following:

	<b>September</b>	<b>December</b>
	<b>30,</b>	<b>31,</b>
	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>	
	<b>(unaudited)</b>	
Subsidiary credit line borrowings (guaranteed by the Company)	\$ 26,500	\$ 22,000
Subsidiary credit line borrowings (not guaranteed by the Company)	12,898	3,014
Subsidiary term loans and other borrowings (guaranteed by the Company)	5,613	3,000

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

	45,011	28,014
Capital lease obligations and other borrowings	2,750	4,202
	47,761	32,216
Less current maturities	(42,929)	(28,206)
Total long-term debt, less current portion	\$ 4,832	\$ 4,010

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

The Company maintains a revolving credit facility that provides for borrowings and issuances of letters of credit and guarantees up to \$75 million. This revolving credit facility expires June 30, 2008. Borrowing availability under the facility is reduced by the amounts outstanding for the Company's borrowings and letters of credit and amounts guaranteed under partner company facilities maintained with that same lender. This credit facility bears interest at the prime rate (7.75% at September 30, 2007) for outstanding borrowings. The credit facility is subject to an unused commitment fee of 0.125%, which is subject to reduction based on deposits maintained at the bank. The facility requires cash collateral equal to one times the Company's borrowings and letters of credit and amounts borrowed by partner companies under the guaranteed portion of the partner company facilities maintained with that same bank.

In November 2006, the Company entered into an additional revolving credit facility with a separate bank that provides for borrowings and issuances of letters of credit and guarantees of up to \$20 million. Borrowing availability under this facility is reduced by the amounts outstanding for the Company's borrowings and letters of credit and amounts guaranteed under partner company facilities maintained with that same lender. This credit facility bears interest at the prime rate for outstanding borrowings. The credit facility is subject to an unused commitment fee of 0.125%, which is subject to reduction based on deposits maintained at the bank. The facility requires cash collateral equal to one times the Company's borrowings and letters of credit and amounts borrowed by partner companies under the guaranteed portion of the partner company facilities maintained at the same bank. As of September 30, 2007, we had no outstanding borrowings under this facility. This credit facility expires in November 2007.

Availability under the Company's revolving credit facilities at September 30, 2007 was as follows (in thousands):

	<b>Total</b>
Size of facilities	\$ 95,000
Subsidiary facilities at same banks (a)	(40,800)
Outstanding letter of credit (b)	(6,336)
Amount available	 \$ 47,864

(a) The Company's availability under its credit facilities is reduced by the amounts borrowed by the Company and letters of credit and amounts guaranteed under partner company facilities maintained at the same respective banks. Of the total facilities,

\$32.1 million was outstanding under these facilities at September 30, 2007 and was included as debt on the Consolidated Balance Sheet.

- (b) In connection with the sale by the Company of CompuCom, Inc. ( CompuCom ), the Company provided to the landlord of CompuCom s Dallas headquarters lease, a letter of credit, which will expire on March 19, 2019, in an amount equal to \$6.3 million.

Alliance Consulting, Clariant and Laureate Pharma maintain credit facilities with one of the same lenders as the Company. Borrowings are secured by substantially all of the assets of the respective subsidiaries. These obligations bear interest at variable rates ranging between the prime rate minus 0.5% and the prime rate plus 0.5%. These facilities contain financial and non-financial covenants. During the three months ended September 30, 2007, Alliance Consulting and Clariant each did not comply with certain of their financial covenants under their respective facilities and subsequently received waivers from the lender, regarding such non-compliance. In addition, Clariant entered into an amendment with the lender to modify its financial covenant requirements on a prospective basis.

In July 2007, Acxis amended and restated its credit facility with its bank, providing up to \$4.5 million of availability, subject to a borrowing base calculation. The facility expires in July 2008 and bears interest at rates ranging from the prime rate plus 1.5% to the prime rate plus 2.25% depending on Acxis liquidity.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

In September 2006, Clariant entered into a \$5 million senior secured revolving credit agreement. Borrowing availability under the agreement is based on the level of Clariant's qualified accounts receivable, less certain reserves. The agreement has a two-year term and bears interest at variable rates based on the lower of the one month London Interbank Offered Rate ( LIBOR ) (4.31% at September 30, 2007) plus 3.25% or the prime rate plus 0.5%. As of September 30, 2007, Clariant had \$4.1 million outstanding borrowings under this facility and had no availability based on the level of qualified accounts receivable. During the three months ended September 30, 2007 Clariant did not comply with certain of its financial covenants under this facility and subsequently received a waiver from the lender, regarding such non-compliance. In addition, Clariant entered into an amendment with the lender to modify its financial covenant requirements on a prospective basis.

Debt as of September 30, 2007 and December 31, 2006 bore interest at fixed rates between 4.62% and 20.33% and variable rates between the prime rate minus 0.5% and the prime rate plus 2.0%.

The Company's debt matures as follows:

	<b>Total (in thousands)</b>
Remainder of 2007	\$ 2,405
2008	41,351
2009	2,814
2010	1,021
2011 and thereafter	170
Total debt	\$ 47,761

**9. CONVERTIBLE SENIOR DEBENTURES**

In February 2004, the Company completed the sale of \$150 million of 2.625% convertible senior debentures with a stated maturity of March 15, 2024. Interest on the 2024 Debentures is payable semi-annually. At the debenture holders' option, the 2024 Debentures are convertible into Company common stock through March 14, 2024, subject to certain conditions. The conversion rate of the debentures is \$7.2174 of principal amount per share. The closing price of the Company's common stock at September 28, 2007 was \$2.29. The 2024 Debenture holders may require repurchase of the debentures on March 21, 2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective face amount, plus accrued and unpaid interest. The 2024 Debenture holders may also require repurchase of the debentures upon certain events, including liquidation, dissolution or a change in control. Subject to certain conditions, the Company may redeem all or some of the 2024 Debentures commencing March 20, 2009. During 2006, the Company repurchased \$21 million of face value of the 2024 Debentures for \$16.4 million in cash, including accrued interest. In connection with the repurchases, the Company recorded \$0.4 million of expense related to the acceleration of deferred debt issuance costs associated with the 2024 Debentures, resulting in a net gain of \$4.3 million, which is included in Other Income (Loss), Net in the Consolidated Statements of Operations. At September 30, 2007, the outstanding 2024 Debentures had a face value of \$129 million and a market value of approximately \$109.4 million, based on quoted market prices.

As required by the terms of the 2024 Debentures, after completing the sale of CompuCom in October 2004, the Company escrowed \$16.7 million for interest payments through March 15, 2009 on the 2024 Debentures. A total of \$5.8 million is included in Restricted Marketable Securities on the Consolidated Balance Sheet at September 30, 2007, of which \$3.9 million is classified as a current asset.

Table of Contents

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

**10. STOCK-BASED COMPENSATION**

On January 1, 2006, the Company adopted SFAS No. 123 (revised 2004), Share-Based Payment ( SFAS No. 123(R) ) using the modified prospective method.

**Classification of Stock-Based Compensation Expense**

Stock-based compensation expense from continuing operations was recognized in the Consolidated Statements of Operations as follows (in thousands):

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>			
	<b>(unaudited)</b>			
Cost of sales	\$ 68	\$ 17	\$ 178	\$ 53
Selling, general and administrative	1,515	1,348	4,873	4,834
Research and development	12	14	61	32
	<b>\$ 1,595</b>	<b>\$ 1,379</b>	<b>\$ 5,112</b>	<b>\$ 4,919</b>

**The Company**

The fair value of the Company's stock-based awards to employees are estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the end of the quarter. The expected life of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility for a period equal to the stock option's expected life.

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(unaudited)</b>			
<b>Service-Based Awards</b>				
Dividend yield	0%	0%	0%	0%
Expected volatility	58%	70%	61%	72%
	5	5	5	5
Average expected option life	years	years	years	years
Risk-free interest rate	4.2%	4.4%	4.5%	4.7%
<b>Market-Based Awards</b>				
Dividend yield	0%	0%	0%	0%
Expected volatility	55%	62%	54%	65%
	6	6	6	6
Average expected option life	years	years	years	years
Risk-free interest rate	4.9%	4.8%	4.9%	4.9%

Market-based awards entitle participants to vest in a number of options determined by achievement of certain target market capitalization increases (measured by reference to stock price increases on a specified number of outstanding shares) over an eight-year period. The requisite service periods for the market-based awards are based on the Company's estimate of the dates on which the market conditions will be met. Compensation expense is recognized

over the requisite service periods using the straight-line method, but is accelerated if market capitalization targets are achieved earlier than estimated. Based on the achievement of market capitalization targets, 0.4 million and 0.9 million shares vested during the three and nine months ended September 30, 2007. The Company recorded \$0.3 million and \$1.4 million of compensation expense related to these awards during the three and nine months ended September 30, 2007 and \$0.3 million and \$1.7 million during the three and nine months ended September 30, 2006, respectively. Depending on the Company's stock performance, the maximum number of unvested shares at September 30, 2007 attainable under these grants was 8.7 million shares.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

All other outstanding options are primarily service-based awards that generally vest over four years from the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. The Company recorded \$0.5 million and \$1.5 million of compensation expense related to these awards during the three and nine months ended September 30, 2007 and \$0.3 million and \$1.1 million during the three and nine months ended September 30, 2006, respectively.

***Consolidated Subsidiaries***

The fair value of the Company's subsidiaries' stock-based awards to employees are estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate is based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected life of stock options granted was estimated using the historical exercise behavior of employees. The expected life of stock options granted for subsidiaries that do not have sufficient historical exercise behavior of employees was calculated using the simplified method of determining expected term as provided in Staff Accounting Bulletin No. 107, Share-Based Payment (SAB 107). Expected volatility for publicly-held subsidiaries was based on historical volatility for a period equal to the stock option's expected life. Expected volatility for privately-held subsidiaries is based on the average historical volatility of comparable companies for a period equal to the stock option's expected life. The fair value of the underlying stock of privately-held subsidiaries on the date of grant was determined based on a number of valuation methods, including discounted cash flows and revenue and acquisition multiples.

Stock options granted by subsidiaries generally are service-based awards that vest over four years from the date of grant and expire 7 to 10 years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period is the period over which the award vests. The Company's consolidated subsidiaries recorded compensation expense related to these awards of \$0.8 million and \$2.2 million during the three and nine months ended September 30, 2007 and \$0.7 million and \$2.1 million during the three and nine months ended September 30, 2006, respectively.

Certain employees of the Company's subsidiaries have the right to require the respective subsidiary to repurchase shares of common stock of the subsidiary received by the employee pursuant to the exercise of options. The employee must hold the shares for at least six months prior to exercising this right. The required repurchase price is 75% to 100% of the fair market value at the time the right is exercised. These options qualify for equity-classification under SFAS No. 123(R). In accordance with EITF Issue No. D-98, however, these instruments are classified outside of permanent equity as redeemable subsidiary stock-based compensation on the Consolidated Balance Sheets at their redemption amount based on the number of options vested as of September 30, 2007 and December 31, 2006, respectively. Following the sale of Pacific Title, amounts payable related to deferred stock units issued to a former employee of Pacific Title were classified in accrued expenses and other current liabilities on the Consolidated Balance Sheet at September 30, 2007 at the expected redemption amount. At December 31, 2006, these instruments were classified outside of permanent equity as redeemable subsidiary stock-based compensation.

**11. INCOME TAXES**

The Company's consolidated income tax benefit for the nine months ended September 30, 2007 was \$0.7 million. The net tax benefit relates to the reversal of reserves that relate to uncertain tax positions for which the statute of limitations expired during the period in the applicable tax jurisdictions and the Company's share of net state tax expense recorded by subsidiaries. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss that would have been recognized in 2007 was offset by a valuation allowance.

Effective January 1, 2007, the Company adopted FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109 (FIN 48). FIN 48 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Adoption of FIN 48 had no impact on the Company's consolidated results of operations and



financial position.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

Upon adoption of FIN 48, the Company identified uncertain tax positions that the Company currently does not believe meet the more likely than not recognition threshold under FIN 48 to be sustained upon examination. Because these uncertain tax positions have not been utilized and had a full valuation allowance established, the Company reduced the gross deferred tax asset and valuation allowance by \$3.2 million. This amount relates to unrecognized tax benefits that would impact the effective tax rate if recognized absent the valuation allowance.

The Company and its consolidated partner companies file income tax returns in the U.S. federal jurisdiction, and various states and foreign jurisdictions. Tax years 2004 and forward remain open for examination for federal tax purposes and tax years 2002 and forward remain open for examination for the Company's more significant state tax jurisdictions. To the extent utilized in future years' tax returns, net operating loss and capital loss carryforwards at September 30, 2007 will remain subject to examination until the respective tax year is closed.

At December 31, 2006, the Company had accrued \$0.8 million for unrecognized tax benefits, including \$0.2 million for the payment of penalties and interest. The Company recognizes penalties and interest accrued related to income tax liabilities in the provision (benefit) for income taxes in its consolidated statements of operations. Substantially all of the unrecognized tax benefits at December 31, 2006 were recognized in the nine months ended September 30, 2007 as the applicable statutes of limitations expired.

**12. NET LOSS PER SHARE**

The calculations of net loss per share were:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands except per share data)</b>			
	<b>(unaudited)</b>			
<b>Basic:</b>				
Net loss from continuing operations	\$ (24,122)	\$ (10,118)	\$ (52,612)	\$ (31,603)
Net income from discontinued operations	72	511	3,332	6,309
Net loss	\$ (24,050)	\$ (9,607)	\$ (49,280)	\$ (25,294)
Average common shares outstanding	122,440	121,541	122,299	121,441
Net loss per share from continuing operations	\$ (0.20)	\$ (0.08)	\$ (0.43)	\$ (0.26)
Net income per share from discontinued operations			0.03	0.05
Net loss per share	\$ (0.20)	\$ (0.08)	\$ (0.40)	\$ (0.21)
<b>Diluted:</b>				
Net loss from continuing operations	\$ (24,122)	\$ (10,118)	\$ (52,612)	\$ (31,603)
Net income from discontinued operations	72	511	3,332	6,309
Effect of holdings		(34)		(49)
Adjusted net loss	\$ (24,050)	\$ (9,641)	\$ (49,280)	\$ (25,343)

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Average common shares outstanding	122,440	121,541	122,299	121,441
Net loss per share from continuing operations	\$ (0.20)	\$ (0.08)	\$ (0.43)	\$ (0.26)
Net income per share from discontinued operations			0.03	0.05
Diluted net loss per share	\$ (0.20)	\$ (0.08)	\$ (0.40)	\$ (0.21)

Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs).

16

---

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs, warrants or securities outstanding, diluted net loss per share is computed by first deducting from net loss the income attributable to the potential exercise of the dilutive securities of the company. This impact is shown as an adjustment to net loss for purposes of calculating diluted net loss per share.

The following potential shares of common stock and their effects on income were excluded from the diluted net loss per share calculation because their effect would be anti-dilutive:

At September 30, 2007 and 2006, respectively, options to purchase 21.6 million and 19.8 million shares of common stock at prices ranging from \$1.03 to \$45.47 per share, were excluded from the calculations;

At September 30, 2007 and 2006, respectively, unvested shares of restricted stock and unvested deferred stock units totaling 0.1 million shares were excluded from the calculations; and

At September 30, 2007 and 2006, respectively, a total of 17.9 million and 19.0 million shares related to the Company's 2024 Debentures (See Note 9) representing the weighted average effect of assumed conversion of the 2024 Debentures were excluded from the calculations.

**13. PARENT COMPANY FINANCIAL INFORMATION**

Parent company financial information is provided to present the financial position and results of operations of the Company as if the consolidated companies (see Note 2) were accounted for under the equity method of accounting for all periods presented during which the Company owned its interest in these companies.

**Parent Company Balance Sheets**

	<b>September 30, 2007</b>	<b>December 31, 2006</b>
	<b>(In thousands)</b>	
	<b>(unaudited)</b>	
Assets:		
Cash and cash equivalents	\$ 106,917	\$ 59,933
Marketable securities	542	94,155
Restricted marketable securities	3,861	3,869
Other current assets	936	1,978
Asset held for sale		17,852
Total current assets	112,256	177,787
Ownership interests in and advances to companies	179,050	160,557
Long-term marketable securities		487
Long-term restricted marketable securities	1,946	5,737
Cash held in escrow	22,439	19,398
Other	2,776	3,377
Total Assets	\$ 318,467	\$ 367,343
Liabilities and Shareholders' Equity:		
Current liabilities	\$ 15,484	\$ 18,816
Long-term liabilities	5,209	5,625
Convertible senior debentures	129,000	129,000
Shareholders' equity	168,774	213,902

Total Liabilities and Shareholders' Equity	\$ 318,467	\$ 367,343
--	------------	------------

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

**Parent Company Statements of Operations**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>			
	<b>(unaudited)</b>			
Operating expenses	\$ (5,870)	\$ (5,050)	\$ (17,609)	\$ (15,994)
Other income (loss), net	(4,419)	3,081	(5,108)	4,958
Interest income	1,763	1,309	6,023	4,346
Interest expense	(1,056)	(1,150)	(3,166)	(3,554)
Equity loss	(14,540)	(8,308)	(33,462)	(22,643)
Net loss from continuing operations before income taxes	(24,122)	(10,118)	(53,322)	(32,887)
Income tax benefit			710	1,284
Equity income attributable to discontinued operations	72	511	3,332	6,309
Net loss	\$ (24,050)	\$ (9,607)	\$ (49,280)	\$ (25,294)

**Parent Company Statements of Cash Flows**

	<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>	
	<b>(unaudited)</b>	
Net cash used in operating activities	\$ (13,214)	\$ (9,076)

**Cash Flows from Investing Activities:**

Proceeds from sales of and distributions from companies and funds	2,359	672
Advances to companies	(1,953)	
Acquisitions of ownership interests in companies and funds, net of cash acquired	(54,054)	(46,887)
Increase in marketable securities	(111,268)	(62,016)
Decrease in marketable securities	204,880	64,370
Capital expenditures	(7)	(93)
Proceeds from sale of discontinued operations	19,655	
Other, net		785
Net cash provided by (used in) investing activities	59,612	(43,169)

**Cash Flows from Financing Activities:**

Repurchase of convertible senior debentures		(16,215)
---	--	----------

Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Decrease in restricted cash		1,098
Repayment of advance from subsidiary		(3,250)
Issuance of company common stock, net	586	356
Net cash provided by (used) in financing activities	586	(18,011)
Net Increase (Decrease) in Cash and Cash Equivalents	46,984	(70,256)
Cash and Cash Equivalents at beginning of period	59,933	108,300
Cash and Cash Equivalents at end of period	\$ 106,917	\$ 38,044

Parent Company cash and cash equivalents exclude marketable securities, which consists of longer-term securities, including commercial paper and certificates of deposit.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

**14. OPERATING SEGMENTS**

The Company presents its consolidated partner companies as separate segments Acsis, Alliance Consulting, Clariant and Laureate Pharma. The results of operations of the Company's non-consolidated partner companies and the Company's ownership in private equity funds are reported in the Other Companies segment. The Other Companies segment also includes the gain or loss on the sale of companies and funds, except for gains and losses included in discontinued operations.

Management evaluates segment performance based on segment revenue, operating income (loss) and income (loss) before income taxes, which reflects the portion of income (loss) allocated to minority shareholders.

Other Items includes certain expenses, which are not identifiable to the operations of the Company's operating business segments. Other Items primarily consists of general and administrative expenses related to corporate operations, including employee compensation, insurance and professional fees including legal, finance and consulting, interest income and interest expense. Other Items also includes income taxes, which are reviewed by management independent of segment results.

The following tables reflect the Company's consolidated operating data by reportable segment. Segment results include the results of the consolidated partner companies, impairment charges, gains or losses related to the disposition of the partner companies, except those reported in discontinued operations, the Company's share of income or losses for entities accounted for under the equity method and the mark-to-market of trading securities. All significant intersegment activity has been eliminated in consolidation. Accordingly, segment results reported by the Company exclude the effect of transactions between the Company and its subsidiaries and among the Company's subsidiaries.

Revenue is attributed to geographic areas based on where the services are performed or the customer's shipped to location. A majority of the Company's revenue is generated in the United States.

As of September 30, 2007 and December 31, 2006, the Company's assets were primarily located in the United States.

The following represents the segment data from continuing operations:

**Three Months Ended September 30, 2007**  
**(in thousands)**  
**(unaudited)**

	Acsis	Alliance Consulting	Clariant	Laureate Pharma	Other Companies	Total Segments	Other Items	Total Continuing Operations
Revenue	\$ 4,848	\$21,674	\$12,058	\$ 7,167	\$	\$ 45,747	\$	\$ 45,747
Operating loss	(1,928)	(6,318)	(2,452)	(159)		(10,857)	(5,870)	(16,727)
Net loss	(1,959)	(6,410)	(1,561)	(441)	(8,700)	(19,071)	(5,051)	(24,122)
<b>Segment Assets</b>								
September 30, 2007	\$22,880	\$78,617	\$39,400	\$30,979	\$91,445	\$263,321	\$139,417	\$402,738
December 31, 2006	27,266	83,766	33,688	25,626	55,035	225,381	188,447	413,828



**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

**Three Months Ended September 30, 2006**  
**(in thousands)**  
**(unaudited)**

	Acis	Alliance Consulting	Clarient	Laureate Pharma	Other Companies	Total Segments	Other Items	Total Continuing Operations
Revenue	\$ 4,156	\$27,527	\$ 7,936	\$ 2,218	\$	\$ 41,837	\$	\$ 41,837
Operating income (loss)	(2,528)	752	(2,828)	(2,735)		(7,339)	(5,050)	(12,389)
Net income (loss)	(2,358)	560	(1,682)	(2,916)	(2,145)	(8,541)	(1,577)	(10,118)

**Nine Months Ended September 30, 2007**  
**(in thousands)**  
**(unaudited)**

	Acis	Alliance Consulting	Clarient	Laureate Pharma	Other Companies	Total Segments	Other Items	Total Continuing Operations
Revenue	\$ 14,203	\$64,524	\$31,251	\$19,010	\$	\$128,988	\$	\$128,988
Operating loss	(6,778)	(9,063)	(8,027)	(2,035)		(25,903)	(17,609)	(43,512)
Net loss	(6,826)	(9,506)	(4,991)	(2,777)	(14,679)	(38,779)	(13,833)	(52,612)

**Nine Months Ended September 30, 2006**  
**(in thousands)**  
**(unaudited)**

	Acis	Alliance Consulting	Clarient	Laureate Pharma	Other Companies	Total Segments	Other Items	Total Continuing Operations
Revenue	\$ 13,141	\$78,607	\$19,817	\$ 6,864	\$	\$118,429	\$	\$118,429
Operating loss	(6,656)	(198)	(9,642)	(7,457)		(23,953)	(15,994)	(39,947)
Net loss	(6,263)	(754)	(5,555)	(7,880)	(1,795)	(22,247)	(9,356)	(31,603)

**Other Items**

	<b>Three Months Ended September 30, 2007</b>		<b>Nine Months Ended September 30, 2006</b>	
	<b>(in thousands)</b> <b>(unaudited)</b>			
Corporate operations	\$ (5,051)	\$ (1,575)	\$ (14,529)	\$ (10,629)
Income tax (expense) benefit		(2)	696	1,273
	\$ (5,051)	\$ (1,577)	\$ (13,833)	\$ (9,356)

**15. BUSINESS COMBINATIONS****Acquisitions by the Company**

In September 2007, the Company increased its ownership interest in NexTone Communications, Inc. ( NexTone ) from 16.1% to 16.6%, for \$2.1 million in cash. NexTone develops carrier-grade products for delivering

scalable control of real-time IP services, such as voice over Internet protocol ( VoIP ). The Company accounts for its holdings in NexTone under the cost method.

In August, 2007, the Company acquired 21.1% of Broadband National, Inc. ( Broadband National ) for \$8.0 million in cash. Broadband National is an internet media company that operates a network of shopping websites focused on digital services and products

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

such as high speed internet, digital phone, VoIP, TV and music. The Company accounts for its holdings in Broadband National under the equity method. The difference between the Company's cost and its interest in the underlying net assets of Broadband National was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In August 2007, the Company acquired 14.0% of a yet-to-be-publicly launched web-based software company for \$2.2 million in cash, which acquisition is accounted for under the cost method.

In June 2007, the Company acquired 40.3% of Cellumen, Inc. ( Cellumen ) for \$6.0 million in cash. Cellumen is a cellular systems biology company whose technology optimizes the drug discovery process. The Company accounts for its holdings in Cellumen under the equity method. The difference between the Company's cost and its interest in the underlying net assets of Cellumen was allocated to in-process research and development, resulting in a \$0.2 million charge in the second quarter of 2007, and to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In June 2007, the Company increased its ownership interest in Authentium, Inc. ( Authentium ) to 19.9%, by deploying an additional \$3.0 million in cash. The Company had previously acquired a 12.4% interest in Authentium in April 2006 for \$5.5 million in cash. Authentium is a provider of security software to internet service providers. The Company accounts for its holdings in Authentium under the cost method.

In May 2007, the Company acquired 14.2% of Avid Radiopharmaceuticals ( Avid ) for \$7.3 million in cash. Avid develops molecular imaging products for neurodegenerative diseases. The Company accounts for its holdings in Avid under the cost method.

In May 2007, the Company increased its ownership interest in Advanced BioHealing, Inc. ( ABH ) to 28.3% for \$2.7 million in cash. The Company had previously acquired a 23.9% interest in ABH in February 2007 for \$8.0 million in cash. ABH is a specialty biotechnology company focused on the development and marketing of cell-based and tissue engineered products. The Company accounts for its holdings in ABH under the equity method. The difference between the Company's cost and its interest in the underlying net assets of ABH was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In March 2007, the Company acquired 37.1% of Beyond.com, Inc. ( Beyond.com ) for \$13.5 million in cash. Beyond.com is a provider of online technology and career services to job seekers and corporations. The Company accounts for its holdings in Beyond.com under the equity method. The difference between the Company's cost and its interest in the underlying net assets of Beyond.com was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In November 2006, the Company acquired 32.2% of Advantedge Healthcare Solutions ( AHS ) for \$5.8 million in cash. AHS is a New York based technology-enabled service provider that delivers medical billing services to physician groups. The Company accounts for its holdings in AHS under the equity method. The difference between the Company's cost and its interest in underlying net assets of AHS was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In September 2006, the Company acquired additional common shares of Clariant for \$3 million in cash to fund Clariant's acquisition of Trestle Holdings, Inc. ( Trestle ). As a result of the funding, the Company's ownership in Clariant increased to 59.6%. The difference between the Company's cost and its interest in the underlying net assets of Clariant was allocated to intangible assets of \$0.8 million with estimated useful lives of 5 years and to fixed assets of \$0.2 million with estimated depreciable lives of 3 years.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

In September 2006, the Company acquired 23.8% of NuPathe, Inc. ( NuPathe ) for \$3 million in cash. NuPathe develops therapeutics in conjunction with novel transdermal delivery technologies. The Company accounts for its holdings in NuPathe under the equity method. The difference between the Company's cost and its interest in the underlying net assets of NuPathe was allocated to in-process-research and development, resulting in a \$1.0 million charge in 2006, and goodwill as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In August 2006, the Company acquired 46.9% of Portico Systems ( Portico ) for \$6 million in cash. Portico is a software solutions provider for regional and national health plans looking to optimize provider network operations and streamline business processes. The Company accounts for its holdings in Portico under the equity method. The difference between the Company's cost and its interest in the underlying net assets of Portico was allocated to intangible assets and goodwill, as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In August 2006, the Company acquired 36.5% of Rubicor Medical, Inc. ( Rubicor ) for \$20 million in cash. Rubicor develops and distributes technologically advanced, disposable, minimally-invasive breast biopsy devices. The Company accounts for its holdings in Rubicor under the equity method. The difference between the Company's cost and its interest in the underlying net assets of Rubicor was allocated to in-process-research and development, resulting in a \$0.6 million charge in 2006, and intangible assets as reflected in the carrying value in Ownership interests in and advances to companies on the Consolidated Balance Sheet.

In June 2006, the Company acquired additional common shares of Acsis for an aggregate purchase price of \$6 million in cash at the same per-share value as the Company's December 2005 acquisition. The result of the June 2006 incremental equity purchase was an increase in ownership in Acsis to 95.5%. The capital provided is being used by Acsis to support its long-term growth strategy.

**16. COMMITMENTS AND CONTINGENCIES**

The Company, and its partner companies, are involved in various claims and legal actions arising in the ordinary course of business, and which may from time to time arise from facility lease terminations. While in the current opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company's consolidated financial position or results of operations, no assurance can be given as to the outcome of these lawsuits, and one or more adverse rulings could have a material adverse effect on the Company's consolidated financial position and results of operations, or that of our companies.

In connection with its ownership interests in certain affiliates, the Company had the following outstanding guarantees at September 30, 2007:

	Amount	Debt Included on Consolidated Balance Sheet (in thousands)
Consolidated company guarantees – credit facilities	\$ 40,800	\$ 32,113
Consolidated company guarantees – other	4,748	
Non-consolidated company guarantees	3,750	
Total	\$ 49,298	\$ 32,113

The Company has committed capital of approximately \$5.4 million, including a conditional commitment to provide a partner company with additional funding and commitments made to various private equity funds in prior years. These commitments will be funded over the next several years, including approximately \$4.6 million which is

expected to be funded during the next twelve months.

**Table of Contents**

**SAFEGUARD SCIENTIFICS, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**SEPTEMBER 30, 2007**

Under certain circumstances, the Company may be required to return a portion or all the distributions it received as a general partner of certain private equity funds (the "clawback"). Assuming the private equity funds in which the Company was a general partner were liquidated or dissolved on September 30, 2007 and assuming for these purposes the only distributions from the funds were equal to the carrying value of the funds on the September 30, 2007 financial statements, the maximum clawback the Company would be required to return for its general partner interest is approximately \$8 million. The Company estimates its liability to be approximately \$6.7 million of which \$5.3 million was reflected in Accrued expenses and other current liabilities and \$1.4 million was reflected in Other long-term liabilities on the Consolidated Balance Sheets.

In anticipation of the sale of Pacific Title in the first quarter of 2007, the Company permitted the employment agreement of the Pacific Title CEO to expire without renewal, and thereby his employment ceased. Following the sale, the former CEO's counsel demanded payment of severance benefits under his employment agreement, as well as payment of his deferred stock units and other amounts substantially in excess of the maximum amounts the Company believed were arguably due. The former CEO and the Company thereafter engaged in negotiations, but were ultimately unable to settle on the appropriate amounts due. On or about August 13, 2007, the former CEO filed a complaint in the Superior Court of the State of California, County of Los Angeles, Central District, against the Company and Pacific Title, alleging, among other things: wrongful termination, conversion, unfair competition, violation of the labor code, breach of contract and negligence. In his complaint, the former CEO makes claims for compensatory damages in excess of \$18 million, plus exemplary and punitive damages and interest. While the Company does not dispute that certain amounts may be due the former CEO under various agreements, the Company and Pacific Title deny the majority of the claims under his complaint and the amounts claimed and intend to vigorously defend against such claims. The Company has engaged counsel to represent the Company and Pacific Title in this matter, and have also put the Company's insurance carriers on notice of the claims. Counsel has answered the complaint and has filed a cross-complaint on the Company's and Pacific Title's behalf. The answer denied the relief sought and the Cross Complaint alleged breach of fiduciary duty and breach of contract. The case is proceeding through the discovery phase. It is the Company's belief that amounts presently reserved in its financial statements in connection with this matter are sufficient to cover any amounts ultimately due under the various agreements that existed between the former CEO and Pacific Title and the Company.

**17. IMPAIRMENT OF OWNERSHIP INTERESTS IN AND ADVANCES TO COMPANIES**

The Company recorded impairment charges of \$4.5 million and \$0.8 million in the third and second quarters of 2007, respectively, for Ventaira Pharmaceuticals, Inc. ( "Ventaira"). Ventaira is a cost method partner company which the Company determined to have experienced an other-than-temporary decline in value in accordance with its policy regarding impairment of ownership interests in and advances to companies. The Ventaira carrying value was \$0 as of September 30, 2007.

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**  
**Cautionary Note concerning Forward-Looking Statements**

This report contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, the industries in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as projects, expects, anticipates, intends, plans, believes, seeks, estimates, should, would, could, will, may, variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements are subject to risks and uncertainties. Factors that could cause actual results to differ materially, include, among others, managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, the ability to execute against our stated strategy, the uncertainty of the future performance of our partner companies, acquisitions and dispositions of interests in partner companies, the inability to manage growth, compliance with government regulation and legal liabilities, additional financing requirements and the effect of economic conditions in the business sectors in which our partner companies operate, all of which are discussed below under the heading Factors that May Affect Future Results, in Item 1A in Safeguard's Annual Report on Form 10-K and updated, as applicable, in Item 1A Risk Factors below. Many of these factors are beyond our ability to predict or control. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report might not occur. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance.

All forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by this cautionary statement. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**Overview**

Safeguard's charter is to build value in growth-stage technology and life sciences businesses. We provide growth capital as well as a range of strategic, operational and management resources to our partner companies. Safeguard participates in expansion financings, carve-outs, management buy-outs, recapitalizations, industry consolidations and early-stage financings. Our vision is to be the preferred catalyst for creating great technology and life sciences companies.

We strive to create long-term value for our shareholders through building value in our partner companies. We help our partner companies in their efforts to increase market penetration, grow revenue and improve cash flow in order to create long-term value. We concentrate on companies that operate in two categories:

*Technology* including companies focused on providing software as a service (SaaS), technology-enabled services and vertical software solutions for analytics, enterprise application, infrastructure, security and communication; and

*Life Sciences* including companies focused on medical devices, molecular diagnostics, drug delivery and specialty pharmaceuticals.

**Principles of Accounting for Ownership Interests in Partner Companies**

The various interests that we acquire in our partner companies and private equity funds are accounted for under three methods: consolidation, equity or cost. The applicable accounting method is generally determined based on our influence over the entity, primarily determined based on our voting interest in the entity.

*Consolidation Method.* Partner companies in which we directly or indirectly own more than 50% of the outstanding voting securities are accounted for under the consolidation method of accounting. Participation of other partner company shareholders in the income or losses of our consolidated partner companies is reflected as Minority interest in the Consolidated Statements of Operations. Minority interest adjusts our consolidated operating results to reflect only our share of the earnings or losses of a consolidated partner company. If there is no minority interest balance remaining on the Consolidated Balance Sheets related to a partner company, we record 100% of the respective consolidated partner company's losses. We record 100% of that partner company's subsequent income, if any, to the

extent of such previously recognized losses in excess of our proportionate share.



**Table of Contents**

*Equity Method.* The partner companies whose results are not consolidated, but over whom we exercise significant influence, are accounted for under the equity method of accounting. We also account for our interests in some private equity funds under the equity method of accounting, based on our respective general and limited partner interests. Under the equity method of accounting, our share of the income or loss of the company is reflected in Equity Loss in the Consolidated Statements of Operations. We report our share of the income or loss of the equity method partner companies on a one quarter lag.

When the carrying value of our ownership interest in an equity method partner company is reduced to zero, no further losses are recorded in our Consolidated Statements of Operations unless we have outstanding guarantee obligations or have committed additional funding to the equity method company. When the equity method partner company subsequently reports income, we will not record our share of such income until it equals the amount of our share of losses not previously recognized.

*Cost Method.* Partner companies not consolidated or accounted for under the equity method are accounted for under the cost method of accounting. Under the cost method, our share of the income or losses of such entities is not included in our Consolidated Statements of Operations. The effect of the change in market value of cost method holdings classified as trading securities is reflected in Other Income (Loss), Net in the Consolidated Statements of Operations.

**Critical Accounting Policies and Estimates**

Accounting policies, methods and estimates are an integral part of consolidated financial statements prepared by management and are based upon management's current judgments. These judgments are normally based on knowledge and experience with regard to past and current events and assumptions about future events. Certain accounting policies, methods and estimates are particularly important because of their significance to the financial statements and because of the possibility that future events affecting them may differ from management's current judgments. While there are a number of accounting policies, methods and estimates affecting our financial statements, areas that are particularly significant include the following:

Revenue recognition;

Recoverability of long-lived assets;

Recoverability of goodwill;

Recoverability of ownership interests in and advances to companies;

Income taxes;

Commitments and contingencies; and

Stock-based compensation.

***Revenue Recognition***

During the three and nine months ended September 30, 2007 and 2006, our revenue from continuing operations was attributable to Acsis, Alliance Consulting, Clariant and Laureate Pharma.

Acsis generates revenue from (i) software fees, which consist of revenue from the licensing of software, (ii) services revenue, which consist of fees from consulting, implementation and training services, plus customer support services, and (iii) hardware and reimbursed project expenses. Acsis recognizes software fees in accordance with Statement of Position No. 97-2, Software Revenue Recognition (SOP 97-2), as amended. Acsis recognizes software license revenue when the following criteria are met: (1) a signed contract is obtained; (2) delivery of the products has occurred; (3) the license fee is fixed or determinable; and (4) collectibility is probable. Acsis generally recognizes license revenue using the residual method when there is vendor-specific objective evidence of the fair values of all undelivered elements in a multiple-element arrangement that is not accounted for using long-term contract accounting. For those contracts that contain significant customization or modifications, license revenue is

recognized using the percentage-of-completion method. Acsis recognizes revenues from professional consulting services under fixed-price arrangements, using the proportional-performance method based on direct labor costs incurred to date as a percentage of total estimated labor costs required to complete the project. Project losses are provided for in their entirety in the period they become known, without regard to the percentage-of-completion. Acsis recognizes hardware revenue upon shipment by the vendor to the customer unless the hardware is an element in an arrangement that includes services that involve significant customization or modifications to software, in which case, hardware revenue is bundled with the software and services are recognized on a percentage-of-completion basis.

**Table of Contents**

Alliance Consulting generates revenue primarily from consulting services. Alliance Consulting generally recognizes revenue when persuasive evidence of an arrangement exists, services are performed, the service fee is fixed or determinable and collectibility is probable. Revenue from services is recognized as services are performed. Alliance Consulting also performs certain services under fixed-price service contracts related to discrete projects. Alliance Consulting recognizes revenue from these contracts using the percentage-of-completion method, primarily based on the actual labor hours incurred to date compared to the estimated total hours of the project. Any losses expected to be incurred on jobs in process are charged to income in the period such losses become known. Changes in estimates of total costs could result in changes in the amount of revenue recognized.

Clariant generates revenue from diagnostic services and recognizes such revenue at the time of completion of services at amounts equal to the contractual rates allowed from third parties including Medicare, insurance companies and, to a small degree, private-pay patients. These expected amounts are based both on Medicare allowable rates and Clariant's collection experience with other third party payors.

Laureate Pharma's revenue is primarily derived from contract manufacturing work, process development services, and formulation and filling. Laureate Pharma may enter into revenue arrangements with multiple deliverables in order to meet its customers' needs. Multiple element revenue agreements are evaluated under Emerging Issues Task Force (EITF) Issue Number 00-21, Revenue Arrangements with Multiple Deliverables, to determine whether the delivered item has value to the customer on a stand-alone basis and whether objective and reliable evidence of the fair value of the undelivered item exists. Deliverables in an arrangement that do not meet the separation criteria in EITF 00-21 are treated as one unit of accounting for purposes of revenue recognition. Revenue is generally recognized upon the performance of services. Certain services are performed under fixed price contracts. Revenue from these contracts is recognized on a percentage of-completion basis. When current cost estimates indicate a loss is expected to be incurred, the entire loss is recorded in the period in which it is identified. Changes in estimates of total costs could result in changes in the amount of revenue recognized.

***Recoverability of Long-Lived Assets***

We test long-lived assets, including property and equipment and amortizable intangible assets, for recoverability whenever events or changes in circumstances indicate that we may not be able to recover the asset's carrying amount. When events or changes in circumstances indicate an impairment may exist, we evaluate the recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset cover the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to recover the carrying value, we measure any impairment loss as the excess of the carrying amount of the asset over its fair value.

The carrying value of net intangible assets at September 30, 2007 was \$10.4 million. The carrying value of net property and equipment at September 30, 2007 was \$35.4 million.

In the third quarter of 2007, we conducted a goodwill impairment review related to Alliance Consulting. See Results of Operations - Alliance Consulting.

***Recoverability of Goodwill***

We conduct a review for impairment of goodwill annually as of December 1st. Additionally, on an interim basis, we assess the impairment of goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that we consider important which could trigger an impairment review include significant underperformance relative to historical or expected future operating results, significant changes in the manner or use of the acquired assets or the strategy for the overall business, divestiture of all or part of the business, significant negative industry or economic trends or a decline in a company's stock price for a sustained period.

We test for impairment at a level referred to as a reporting unit (same as or one level below an operating segment as defined in SFAS No. 131, Disclosures About Segments of an Enterprise and Related Information). If we determine that the fair value of a reporting unit is less than its carrying value, we assess whether goodwill of the reporting unit is impaired. To determine fair value, we use a number of valuation methods including quoted market prices, discounted cash flows and revenue and acquisition multiples. Depending on the complexity of the valuation and the significance of the carrying value of the goodwill to the Consolidated Financial Statements, we may engage an outside valuation firm to assist us in determining fair value. As an overall check on the reasonableness of the fair values attributed to our reporting units, we will consider



**Table of Contents**

comparing and contrasting the aggregate fair values for all reporting units with our average total market capitalization for a reasonable period of time.

In the third quarter of 2007, we conducted a goodwill impairment review related to Alliance Consulting, resulting in a \$5.4 million impairment. See Results of Operations Alliance Consulting.

The carrying value of goodwill at September 30, 2007 was \$77.0. million.

Our partner companies operate in industries which are rapidly evolving and extremely competitive. It is reasonably possible that our accounting estimates with respect to the ultimate recoverability of the carrying value of goodwill could change in the near term and that the effect of such changes on our Consolidated Financial Statements could be material. While we believe that the current recorded carrying value of our goodwill is not impaired, there can be no assurance that a significant write-down or write-off will not be required in the future. Impairment charges related to goodwill of consolidated partner companies are included in Goodwill impairment in the Consolidated Statements of Operations.

***Recoverability of Ownership Interests In and Advances to Companies***

On a continuous basis (but no less frequently than at the end of each quarterly period) we evaluate the carrying value of our equity and cost method companies for possible impairment based on achievement of business plan objectives and milestones, the fair value of each company relative to its carrying value, the financial condition and prospects of the company and other relevant factors. We then determine whether there has been an other than temporary decline in the carrying value of our ownership interest in the company. Impairment to be recognized is measured by the amount by which the carrying value of the assets exceeds the fair value of the assets.

The fair value of privately held companies is generally determined based on the value at which independent third parties have invested or have committed to invest in these companies or based on other valuation methods including discounted cash flows, valuation of comparable public companies and the valuation of acquisitions of similar companies. The fair value of our ownership interests in private equity funds is generally determined based on the value of our pro rata portion of the funds net assets and estimated future proceeds from sales of investments provided by the funds managers.

The new cost basis of a company is not written-up if circumstances suggest the value of the company has subsequently recovered.

Our partner companies operate in industries which are rapidly evolving and extremely competitive. It is reasonably possible that our accounting estimates with respect to the ultimate recoverability of the carrying value of ownership interests in and advances to partner companies, including goodwill, could change in the near term and that the effect of such changes on our Consolidated Financial Statements could be material. While we believe that the current recorded carrying values of our equity and cost method partner companies are not impaired, there can be no assurance that our future results will confirm this assessment or that a significant write-down or write-off of the carrying value will not be required in the future.

We recorded impairment charges of \$4.5 million and \$0.8 million in the third and second quarters of 2007, respectively, for Ventaira. Ventaira is a cost method partner company which we determined to have experienced an other-than-temporary decline in value in accordance with our policy regarding impairment of ownership interests in and advances to companies. The Ventaira carrying value was \$0 as of September 30, 2007.

***Income Taxes***

We are required to estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our Consolidated Balance Sheet. We must assess the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent that we believe recovery is not likely, we must establish a valuation allowance. To the extent we establish a valuation allowance in a period, we must include an expense within the tax provision in the Consolidated Statements of Operations. We have recorded a valuation allowance to reduce our deferred tax asset to an amount that is more likely than not to be realized in future years. If we determine in the future that it is more likely than not that the net deferred tax assets would be realized, then the previously provided valuation allowance would be reversed.



**Table of Contents*****Commitments and Contingencies***

From time to time, we are a defendant or plaintiff in various legal actions which arise in the normal course of business. Additionally, we have received distributions as both a general partner and a limited partner from certain private equity funds. Under certain circumstances, we may be required to return a portion or all the distributions we received as a general partner to the fund for a further distribution to the fund's limited partners (the "clawback"). We are also a guarantor of various third-party obligations and commitments, and are subject to the possibility of various loss contingencies arising in the ordinary course of business. We are required to assess the likelihood of any adverse outcomes to these matters as well as potential ranges of probable losses. A determination of the amount of provision required for these commitments and contingencies, if any, which would be charged to earnings, is made after careful analysis of each matter. The provision may change in the future due to new developments or changes in circumstances. Changes in the provision could increase or decrease our earnings in the period the changes are made.

***Stock-based Compensation***

On January 1, 2006, we adopted SFAS No. 123 (revised 2004), "Share-Based Payment" (SFAS No. 123(R)). SFAS No. 123(R) requires companies to measure all employee stock-based compensation awards using a fair value method and to record such expense in its consolidated financial statements.

We estimate the grant date fair value of stock options using the Black-Scholes option-pricing model which requires the input of highly subjective assumptions. These assumptions include estimating the expected term of the award and the estimated volatility of our stock price over the expected term. Changes in these assumptions and in the estimated forfeitures of stock option awards can materially affect the amount of stock-based compensation recognized in the Consolidated Statements of Operations. In addition, the requisite service periods for market-based stock option awards are based on our estimate of the dates on which the market conditions will be met as determined using a Monte Carlo simulation model. Changes in the derived requisite service period or achievement of market capitalization targets earlier than estimated can materially affect the amount of stock-based compensation recognized in the Consolidated Statements of Operations.

***Results of Operations***

We present our consolidated partner companies as separate segments: Acsis, Alliance Consulting, Clariant and Laureate Pharma. The results of operations of our other partner companies in which we have less than a majority interest and our ownership in private equity funds are reported in a segment called "Other Companies." This segment also includes the gain or loss on the sale of companies and funds, except for gains and losses included in discontinued operations.

Our management evaluates segment performance based on segment revenue, operating income (loss) and income (loss) before income taxes, which reflects the portion of income (loss) allocated to minority shareholders.

Other items includes certain expenses which are not identifiable to the operations of our operating business segments. Other items primarily consists of general and administrative expenses related to our corporate operations, including employee compensation, insurance and professional fees, including legal, finance and consulting. Other items also includes interest income, interest expense and income taxes, which are reviewed by management independent of segment results.

The following tables reflect our consolidated operating data by reportable segment. Each segment includes the results of our consolidated companies and records our share of income or losses for entities accounted for under the equity method when applicable. Segment results also include impairment charges, gains or losses related to the disposition of partner companies, except for those reported in discontinued operations and the mark-to-market of trading securities. All significant inter-segment activity has been eliminated in consolidation. Accordingly, segment results reported by us exclude the effect of transactions between us and our subsidiaries and among our subsidiaries.

**Table of Contents**

The Company's operating results including net income (loss) before income taxes by segment were as follows:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
Acsis	\$ (1,959)	\$ (2,358)	\$ (6,826)	\$ (6,263)
Alliance Consulting	(6,410)	560	(9,506)	(754)
Clariant	(1,561)	(1,682)	(4,991)	(5,555)
Laureate Pharma	(441)	(2,916)	(2,777)	(7,880)
Other companies	(8,700)	(2,145)	(14,679)	(1,795)
<b>Total segments</b>	<b>(19,071)</b>	<b>(8,541)</b>	<b>(38,779)</b>	<b>(22,247)</b>
Other items				
Corporate operations	(5,051)	(1,575)	(14,529)	(10,629)
Income tax (expense) benefit		(2)	696	1,273
<b>Total other items</b>	<b>(5,051)</b>	<b>(1,577)</b>	<b>(13,833)</b>	<b>(9,356)</b>
<b>Net loss from continuing operations</b>	<b>(24,122)</b>	<b>(10,118)</b>	<b>(52,612)</b>	<b>(31,603)</b>
<b>Net income from discontinued operations</b>	<b>72</b>	<b>511</b>	<b>3,332</b>	<b>6,309</b>
<b>Net Loss</b>	<b>\$ (24,050)</b>	<b>\$ (9,607)</b>	<b>\$ (49,280)</b>	<b>\$ (25,294)</b>

There is intense competition in the markets in which these companies operate, and we expect competition to intensify in the future. Additionally, the markets in which these companies operate are characterized by rapidly changing technology, evolving industry standards, frequent introduction of new products and services, shifting distribution channels, evolving government regulation, frequently changing intellectual property landscapes and changing customer demands. Their future success depends on each company's ability to execute its business plan and to adapt to its respective rapidly changing markets.

**Acsis**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
Revenue	\$ 4,848	\$ 4,156	\$ 14,203	\$ 13,141
Operating expenses:				
Cost of sales	3,658	2,755	10,644	9,249
Selling, general and administrative	2,359	2,930	7,671	7,708
Research and development	495	616	1,876	1,697
Amortization of intangibles	264	383	790	1,143
<b>Total operating expenses</b>	<b>6,776</b>	<b>6,684</b>	<b>20,981</b>	<b>19,797</b>
<b>Operating loss</b>	<b>(1,928)</b>	<b>(2,528)</b>	<b>(6,778)</b>	<b>(6,656)</b>



Edgar Filing: SAFEGUARD SCIENTIFICS INC - Form 10-Q

Interest, net	(31)	59	(48)	69
Minority interest		111		324
Net loss before income taxes	\$ (1,959)	\$ (2,358)	\$ (6,826)	\$ (6,263)

Acsis is a leading provider of software and service solutions that assist companies in improving efficiencies and enabling safe and secure supply-chains. Its solutions enable manufacturers to automate plant floor/warehouse operations and take advantage of emerging automated-ID technologies, including radio frequency identification ( RFID ) and barcode.

Acsis draws from a variety of technologies and service offerings to create a solution that matches the client s business, budget and IT environment. Its solutions include the next generation of shop floor process automation and data collection using their xDDi enterprise solution suite and xDDI Appliances (intelligent appliances that support RFID and barcode-based product tracking for warehouse, manufacturing, packing and shipping operations). Other solutions include Enterprise Label Management, which enables users to design and generate customer-specific label forms directly for SAP ERP data and manage from a central location and value-added services for implementing SAPConsole and xMII. If requested, Acsis will provide all necessary hardware, consulting services and software to deliver a turnkey data-collection / supply chain solution.

**Table of Contents**

Acsis competition generally comes from large, diversified software or consulting businesses or niche providers with a variety of individual solutions for barcode, RFID or other data collection systems. Acsis differentiates itself by proving a single, integrated platform which can be used across the entire supply-chain to increase efficiencies and reduce operational costs.

Acsis revenue is derived from (i) software fees, which consist of revenue from the licensing of software, (ii) services revenue, which consist of fees from consulting, implementation and training services, plus customer support services; and (iii) hardware and reimbursed project expenses.

At September 30, 2007, we owned a 96.2% voting interest in Acsis.

*Three months ended September 30, 2007 versus three months ended September 30, 2006*

*Revenue.* Revenue increased \$0.7 million or 16.7% in 2007 as compared to the prior year period. The increase was primarily due to a \$1.1 million increase in hardware revenue and a \$0.1 million increase in software fees, partially offset by a \$0.5 million decline in services revenue. Hardware sales fluctuate significantly from period to period given the timing of customer orders.

*Cost of Sales.* Cost of sales increased \$0.9 million, or 32.8% in 2007 as compared to the prior year period. The increase is primarily due to the increase in hardware sales volume. Gross margins were 24.5% and 33.7% for the three months ended September 30, 2007 and 2006, respectively. Gross margins declined 9.2% in 2007 as compared to the prior year period due to additional resources needed in 2007 related to the implementation of several projects.

*Selling, General and Administrative.* Selling, general and administrative expenses decreased \$0.6 million or 19.5% as compared to the prior year period. Selling, general and administrative expenses were 48.7% of revenue in 2007 and 70.5% of revenue in 2006. The decrease was primarily attributable to a decline in severance costs associated with several executives in 2006.

*Research and Development.* Research and development expenses decreased \$0.1 million or 19.6% in 2007 as compared to the prior year period. The decrease was a result of a decline in costs associated with the use of outside contractors.

*Amortization of Intangibles.* Amortization of intangibles decreased \$0.1 million or 31.1% as compared to the prior year period. The decrease was due to an intangible asset with a life of one year that was fully amortized in 2006.

*Net Loss Before Income Taxes.* Net loss decreased \$0.4 million or 16.9% as compared to the prior year period. The increase was attributable to increased revenue as well as reductions in selling general and administrative expenses and research and development expenses.

*Nine months ended September 30, 2007 versus nine months ended September 30, 2006*

*Revenue.* Revenue increased \$1.1 million or 8.1% in 2007 as compared to the prior year period. The increase was due to a \$0.7 million increase in hardware revenue and a \$0.5 million increase in software fees partially offset by a \$0.1 million decline in services revenue. The software fees increase was driven by certain license agreements signed during late 2006. Hardware sales fluctuate significantly from period to period due to the timing of customer orders.

*Cost of Sales.* Cost of sales increased \$1.4 million or 15.1% in 2007 as compared to the prior year period. The increase is primarily due to an increase in service costs of \$0.7 million and hardware costs of \$0.5 million. The increase in hardware costs was directly attributed to the increase in hardware sales volume, while the increase in service costs was a result of additional resources related to the implementation of several projects. Gross margins were 25.1% and 29.6% for the nine months ended September 30, 2007 and 2006, respectively. Gross margins declined 4.5% in 2007 as compared to the prior year period due to additional resources needed in 2007 related to the implementation of several projects. Gross margins are expected to modestly improve in the remainder of 2007 as compared to the first nine months of 2007 due to expected operating efficiencies.

**Table of Contents**

*Selling, General and Administrative.* Selling, general and administrative expenses remained constant in 2007 as compared to the prior year period. Selling, general and administrative expenses were 54.0% of revenue in 2007 and 58.6% of revenue in 2006.

*Research and Development.* Research and development expenses increased \$0.2 million or 10.5% in 2007 as compared to the prior year period. The increase was a result of costs associated with the development of new product offerings.

*Amortization of Intangibles.* Amortization of intangibles decreased \$0.4 million or 30.9% as compared to the prior year period. The decrease was due to an intangible asset with a life of one year that was fully amortized in 2006.

*Net Loss Before Income Taxes.* Net loss slightly increased as compared to the prior year period. Increases in revenue and reductions in selling, general and administrative costs were partially offset by increases in cost of sales and research and development.

**Alliance Consulting**

Alliance Consulting operates on a 52 or 53-week fiscal year, ending on the Saturday closest to the end of the fiscal period. Alliance Consulting's third quarter ended on September 29, 2007 and September 30, 2006, each a period of 13 weeks, and year-to-date a period of 39 weeks, respectively. The financial information presented below does not include the results of operations of Alliance Consulting's Southwest region business, which is included in discontinued operations for the periods prior to its sale.

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
Revenue	\$ 21,674	\$ 27,527	\$ 64,524	\$ 78,607
Operating expenses:				
Cost of sales	16,100	18,863	47,940	55,508
Selling, general and administrative	6,192	7,649	19,424	22,547
Amortization of intangibles	262	263	785	750
Goodwill impairment	5,438		5,438	
Total operating expenses	27,992	26,775	73,587	78,805
Operating income (loss)	(6,318)	752	(9,063)	(198)
Other income, net	171	34	214	53
Interest, net	(310)	(219)	(729)	(602)
Minority interest	47	(7)	72	(7)
Net income (loss) before income taxes	\$ (6,410)	\$ 560	\$ (9,506)	\$ (754)

Alliance Consulting is a leading national business intelligence consultancy providing services primarily to Fortune 2000 clients in the pharmaceutical, financial services and manufacturing industries. Alliance Consulting specializes in information management, which is comprised of a full range of business intelligence solutions from data acquisition and warehousing to master data management, analytics and reporting, and application services, which includes software development, integration, testing and application support delivered through a high quality and cost effective hybrid global delivery model. Alliance Consulting has developed a strategy focused on enabling business intelligence through the application of deep domain experience and custom-tailored project teams to deliver software solutions and consulting services.

While global economic conditions continue to cause companies to be cautious about increasing their use of consulting and IT services, Alliance Consulting expects to see stable demand for its services. However, Alliance Consulting continues to experience pricing pressure from competitors as well as from clients facing pressure to control costs. In addition, the growing use of offshore resources to provide lower cost service delivery capabilities within the industry continues to place pressure on pricing and revenue. Alliance Consulting expects to continue to focus on maintaining and growing its blue-chip client base and providing high quality solutions and services to its clients.

**Table of Contents**

In July 2006, Alliance Consulting completed the purchase of specific assets and assumed certain liabilities of Fusion Technologies, Inc., ( Fusion ) a provider of strategic information technology solutions to rapidly growing organizations within the United States, increasing Alliance Consulting's substantial offshore capabilities for new and existing clients.

In the third quarter of 2007, we conducted a goodwill impairment review related to the Alliance Consulting segment, due to underperformance relative to historical and expected operating results. We engaged an outside valuation firm to assist in determining the fair value of Alliance Consulting using valuation methods which included discounted cash flows and revenue and acquisition multiples for comparable public companies. We determined that the carrying value of Alliance Consulting exceeded its fair value, indicating a potential impairment of goodwill. We then estimated the implied fair value of the Alliance Consulting goodwill. The excess of the carrying value of goodwill over the implied fair value of goodwill was \$5.4 million, which amount was recognized as an impairment loss within Goodwill impairment in the Consolidated Statements of Operations.

At September, 2007, we owned 99.3% of Alliance Consulting.

*Three months ended September 29, 2007 versus three months ended September 30, 2006*

*Revenue.* Revenue, including reimbursement of expenses, decreased \$5.9 million, or 21.3% in 2007 as compared to the prior year period. The decrease was due to the completion of several significant contracts and the deferral of several new engagements. Recently, Alliance Consulting developed and is implementing an improvement plan, which includes improving sales team productivity, implementing delivery management efficiencies, and discontinuing lower margin projects.

*Cost of Sales.* Cost of sales decreased \$2.8 million, or 14.6% in 2007 as compared to the prior year period. This decrease was primarily a result of the decline in revenue. Gross margins were 25.7% and 31.5% for the three months ended September 30, 2007 and 2006, respectively. Gross margins declined 5.8% in 2007 as compared to the prior year period due to the decline in revenue and certain low margin engagements in the current year, combined with the fixed nature of certain costs. Alliance expects gross margins to improve in the next twelve months due to the completion of certain lower margin engagements and the expected replacement with more profitable projects, improved delivery efficiencies as a result of internal quality initiatives being implemented and improved leverage of fixed costs as revenue grows.

*Selling, General and Administrative.* Selling, general and administrative expenses decreased \$1.5 million, or 19.0% in 2007 as compared to the prior year period. Selling, general and administrative expenses were 28.5% of revenue in 2007 versus 27.8% of revenue for the prior year period. Contributing to the decrease is the decline in variable compensation as a result of decreased operating results during the third quarter of 2007 as compared to the prior year period. The decrease is also due to insurance recovery of legal fees for a case successfully defended. Also, travel and entertainment related expenses declined due to decreased sales. Selling, general and administrative costs are expected to increase; however, as a percentage of revenue, it is expected to decline.

*Interest, Net.* Interest expense increased \$0.1 million or 41.6% in 2007 as compared to the prior year period primarily as a result of higher average outstanding borrowings under the credit facility and an increase in interest rates.

*Net Loss Before Income Taxes.* Net loss increased \$7.0 million or over 100% in 2007 as compared to the prior year period. The increase was primarily related to Alliance Consulting's \$5.4 million goodwill impairment charge in the third quarter of 2007 and a decrease in revenue, partially offset by decreases in cost of sales and selling, general and administrative expenses.

*Nine months ended September 30, 2007 versus nine months ended September 30, 2006*

*Revenue.* Revenue, including reimbursement of expenses, decreased \$14.1 million, or 17.9% in 2007 as compared to the prior year period. This decrease was due to delays by customers in starting projects and the completion of several significant contracts.

*Cost of Sales.* Cost of sales decreased \$7.6 million, or 13.6% in 2007 as compared to the prior year period. This decrease was primarily a result of the decline in revenue. Gross margins were 25.7% and 29.4% for the nine months ended September 2007 and 2006, respectively. Gross margins declined 3.7% in 2007 as compared to the prior year period due to the decline in revenue and the fixed nature of certain costs.



**Table of Contents**

*Selling, General and Administrative.* Selling, general and administrative expenses decreased \$3.1 million, or 13.9% in 2007 as compared to the prior year period. Contributing to the decrease is the decline in variable compensation as a result of decreased operating results during 2007. The decrease is also due to insurance recovery of legal fees for a case successfully defended. Also, travel and entertainment related expenses declined due to decreased sales. Severance and restructuring costs decreased due a restructuring charge of \$0.5 million to consolidate multiple facilities within the same geographic market and severance costs of approximately \$0.3 million recognized during the prior year period. Selling, general and administrative expenses were 30.1% of revenue in 2007 as compared to 28.7% of revenue in 2006.

*Interest, Net.* Interest expense increased slightly in 2007 as compared to the prior year period due to higher average outstanding borrowings and an increase in interest rates.

*Net Loss Before Income Taxes.* Net loss increased \$8.8 million or over 100% in 2007 as compared to the prior year period. The increase was primarily related to Alliance Consulting's \$5.4 million goodwill impairment charge in the third quarter of 2007 and decreased revenue as compared to the prior year period, partially offset by decreases in cost of sales and selling, general and administrative expenses.

**Clariant**

The financial information presented below does not include the results of operations of Clariant's technology group business, which is included in discontinued operations for all periods presented. Clariant sold this business (which developed, manufactured and marketed the ACIS Automated Image Analysis System) and related intellectual property to Carl Zeiss MicroImaging, Inc. (the ACIS Sale) for net cash proceeds of \$10.3 million, excluding contingent purchase price of \$1.5 million. In the first quarter of 2007, prior to its sale, the technology group business generated revenue of \$0.8 million, net loss from operations of \$0.6 million and a gain on disposal of \$3.6 million. The technology group business generated revenue of \$1.1 million and \$2.4 million, with net loss from operations of \$0.9 million and \$1.5 million for the three and six months ended June 30, 2006.

	<b>Three Months Ended September 30, 2007</b>		<b>Nine Months Ended September 30, 2007</b>	
	<b>2006</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
Revenue	\$ 12,058	\$ 7,936	\$ 31,251	\$ 19,817
Operating expenses:				
Cost of sales	5,757	4,406	16,373	11,125
Selling, general and administrative	8,753	6,358	22,905	18,334
Total operating expenses	14,510	10,764	39,278	29,459
Operating loss	(2,452)	(2,828)	(8,027)	(9,642)
Other loss, net		(39)		(39)
Interest, net	(286)	(143)	(897)	(241)
Minority interest	1,177	1,328	3,933	4,367
Net loss before income taxes	\$ (1,561)	\$ (1,682)	\$ (4,991)	\$ (5,555)

Clariant is a comprehensive cancer diagnostics company providing cellular assessment and cancer characterization to community pathologists, academic researchers, university hospitals and biopharmaceutical companies.

The decision to provide in-house laboratory services was made in 2004 to give Clariant an opportunity to capture a significant service-related revenue stream over the much broader and expanding cancer diagnostic testing

marketplace. Clariant believes it is well-positioned to participate in this growth due to its strength as a cancer diagnostics laboratory, deep domain expertise and access to intellectual property which can contribute to the development of additional tests, unique analytical capabilities and other service offerings.

Clariant operates primarily in one business, the delivery of critical oncology testing services to community pathologists, biopharmaceutical companies and other researchers.

As of September 30, 2007, we owned a 59.6% voting interest in Clariant.



**Table of Contents***Three months ended September 30, 2007 versus three months ended September 30, 2006*

*Revenue.* Revenue increased 51.9% or \$4.1 million from \$7.9 million in the third quarter of 2006 to \$12.1 million in the third quarter of 2007. This increase resulted from the execution of Clariant's marketing and sales strategy to increase its sales to new and existing customers. Clariant added 53 new customers in the third quarter and has increased its penetration to existing customers in the quarter. This increase was also driven in part by expanding test offerings to include immunohistochemistry, flow cytometry and fluorescent in-situ hybridization ( FISH ). Clariant anticipates that its revenue will continue to increase as a result of increased revenue from existing customers, additions of new customers (including managed care providers) by its sales force, and its offering of a more comprehensive suite of advanced cancer diagnostic tests.

*Cost of Sales.* Cost of sales for the quarter ended September 30, 2007 was \$5.8 million compared to \$4.4 million for the third quarter of 2006, an increase of 30.7%. These costs included laboratory personnel, lab-related depreciation expense, laboratory reagents and supplies and other direct costs such as shipping. Gross margin in the third quarter of 2007 was 52.3%, compared to 44.5% in the comparable period in 2006. The increase in gross margin in the third quarter of 2007 was attributable to achieving further economies of scale in Clariant's operations and a shift to more profitable tests. Clariant anticipates similar gross margins for the remainder of 2007.

*Selling, General and Administrative Expenses.* Selling, general and administrative expenses for the third quarter 2007 increased \$2.4 million, or 37.7% to \$8.8 million from \$6.4 million for the comparable period in 2006. As a percentage of revenue, these expenses decreased from 80.1% for the quarter ended September 30, 2006 to 72.6% for the quarter ended September 30, 2007. The increase in expenses in 2007 was due primarily to expenses to generate and support revenue growth and to improve infrastructure, including selling and marketing expenses and billing and collection costs. In addition, Clariant has increased headcount and consulting resources in information technology to support future revenue growth and has incurred incremental stock-based compensation expense for employees due to stock options issued in the quarter. Clariant incurred severance costs of \$0.4 million due to the termination of two senior executives in the quarter and incurred higher professional fees. Clariant anticipates that sales expenses will continue to grow in 2007 to support its expected revenue growth, and expects general and administrative expenses to decline as a percentage of revenues as its infrastructure costs stabilize and due to the nature of certain costs incurred in the quarter.

*Interest, Net.* Interest expense for the three months ended September 30, 2007 totaled \$0.3 million, compared to \$0.1 million for the comparable period in 2006. The increase was due to higher average outstanding borrowings under Clariant's financing facilities.

*Net Loss Before Income Taxes.* Net loss decreased \$0.1 million, or 7.2% in 2007 as compared to the prior year period. The decline in net loss was primarily attributable to margins from increased revenues.

*Nine months ended September 30, 2007 versus six months ended September 30, 2006*

*Revenue.* Revenue for the nine months ended September 30, 2007 was \$31.3 million compared to \$19.8 million for the same period of 2006, an increase of 57.7% or \$11.4 million. This increase resulted from the execution of Clariant's marketing and sales strategy to increase sales to new and existing customers, and to enter into new managed care contracts. Clariant added 153 new customers in 2007 and has increased its penetration to existing customers in the quarter. This increase was also driven in part by expanding Clariant's test offerings to include immunohistochemistry, flow cytometry and FISH. Clariant anticipates that revenue will continue to increase as a result of increased sales from existing customers, additions of new customers (including managed care providers) and Clariant's offering of a more comprehensive suite of advanced cancer diagnostic tests.

*Cost of Sales.* Cost of sales for the nine months ended September 30, 2007 was \$16.4 million, compared to \$11.1 million for the comparable period of 2006, an increase of 47.2%. These costs include laboratory personnel, lab-related depreciation expense, laboratory reagents and supplies and other direct costs such as shipping. Gross margin for the nine months ended September 30, 2007 was 47.6%, compared to 43.9% in the comparable period of 2006. The increase in gross margin in 2007 was attributable to achieving economies of scale within operations and a shift to more profitable tests. Clariant anticipates similar gross margins for the remainder of 2007.

*Selling, General and Administrative Expenses.* Selling, general and administrative expenses for the nine months ended September 30, 2007 increased \$4.6 million, or 24.9%, to \$22.9 million compared to \$18.3 million for the

comparable period in 2006. As a percentage of revenue, these expenses decreased from 92.5% for the nine months ended September 30, 2006 to 73.3% for the nine months ended September 30, 2007. The increase in expenses in 2007 was due primarily to expenses to generate and support revenue growth and to improve

**Table of Contents**

infrastructure, including selling and marketing expenses, billing and collection costs, bad debt, and facility overhead to expand service capacity. Clariant increased headcount and consulting resources in information technology to support future revenue growth throughout 2007. Clariant incurred incremental stock-based compensation expense for options issued in 2007, higher professional fees and severance costs of \$0.5 million due to the termination of senior executives. Clariant anticipates that sales expenses will continue to grow throughout 2007 to support its expected revenue growth, and expects general and administrative expenses to decline as a percentage of revenues as its infrastructure costs stabilize.

*Interest, Net.* Interest expense for the nine months ended September 30, 2007 was \$0.9 million, compared to \$0.2 million for the comparable period of 2006. The increase was due to higher outstanding borrowings under Clariant's financing facilities.

*Net Loss Before Income Taxes.* Net loss decreased \$0.6 million, or 10.2% in 2007 as compared to the prior year period. The decline in net loss was primarily attributable to margins from increased revenues.

**Laureate Pharma**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
Revenue	\$ 7,167	\$ 2,218	\$ 19,010	\$ 6,864
Operating expenses:				
Cost of sales	5,894	3,795	16,745	10,712
Selling, general and administrative	1,432	1,158	4,300	3,609
Total operating expenses	7,326	4,953	21,045	14,321
Operating loss	(159)	(2,735)	(2,035)	(7,457)
Interest, net	(282)	(181)	(742)	(423)
Net loss before income taxes	\$ (441)	\$ (2,916)	\$ (2,777)	\$ (7,880)

Laureate Pharma is a full-service Contract Manufacturing Organization (CMO) providing critical development and Current Good Manufacturing Practices (cGMP) manufacturing services. Laureate Pharma seeks to become a leader in this segment of the biopharmaceutical industry by delivering superior development and manufacturing services to its customers.

Laureate Pharma's broad range of services includes: bioprocessing, aseptic filling, quality control and quality assurance. Laureate Pharma provides process development and manufacturing services on a contract basis to biopharmaceutical companies. Laureate Pharma operates a facility in Princeton, New Jersey.

Laureate Pharma's customers generally include biotechnology and pharmaceutical companies seeking outsourced bioprocessing manufacturing and development services. Laureate Pharma's customers are often dependent on the availability of funding to pursue drugs that are in early stages of clinical trials, and thus have high failure rates. The loss of one or more customers can result in significant swings in profitability from quarter to quarter and year to year. Although there has been a trend among biopharmaceutical companies to outsource drug production functions, this trend may not continue. Laureate Pharma's customer contracts are generally for periods of one to two years. As a result, Laureate Pharma seeks new contracts to sustain its revenue.

As of September 30, 2007, we owned a 100% voting interest in Laureate Pharma.

*Three months ended September 30, 2007 versus three months ended September 30, 2006*

*Revenue.* Revenue increased \$4.9 million, or 223.1% in 2007 as compared to the prior year period. The increase was due to a \$2.9 million increase in manufacturing revenue, a \$0.8 million increase in process development services, \$0.6 million increase in aseptic filling, a \$0.5 million increase in reimbursement from customers for materials and a \$0.1 million increase in support services revenue. Non-reimbursement revenue is expected to remain consistent during the fourth quarter of 2007 as compared to the first three quarters of 2007.

**Table of Contents**

*Cost of Sales.* Cost of sales increased \$2.1 million, or 55.3% in 2007 as compared to the prior year period. The increase was due to an increase in production volume, including a \$0.9 million increase in direct materials and lab supplies, a \$0.7 million increase in compensation expense resulting from additional staffing requirements, a \$0.4 million increase in reimbursable expenses for specific customer materials and a \$0.1 million increase in support services costs. Gross margins were 17.8% and (71.1)% for the three months ended September 30, 2007 and September 30, 2006, respectively. The improvement in gross margins in 2007 as compared to the prior year period is primarily due to increased manufacturing and filling revenues and the fixed nature of certain costs. Laureate expects gross margins to remain consistent during the fourth quarter of 2007 as compared to the first three quarters of 2007.

*Selling, General and Administrative.* Selling, general, and administrative expenses increased \$0.3 million, or 23.7% in 2007 as compared to the prior year period. The increase was due to a \$0.2 million increase in administrative support costs and a \$0.1 million increase in compensation expense resulting from additional staffing. Selling, general and administrative expenses were 20.0% of revenue in the third quarter of 2007 as compared to 52.2% in the prior year period. Selling, general and administrative expenses are expected to slightly increase during the fourth quarter of 2007 as compared to the fourth quarter of 2006 due to additional marketing activities and administrative support costs.

*Interest, Net.* Interest expense increased \$0.1 million in 2007 as compared to the prior year period. The increase was primarily a result of higher average outstanding borrowings.

*Net Loss Before Income Taxes.* Net loss decreased \$2.5 million, or 84.9% in 2007 as compared to the prior year period. The decline in net loss was primarily attributable to margins from increased revenues.

*Nine months ended September 30, 2007 versus nine months ended September 30, 2006*

*Revenue.* Revenue increased \$12.1 million, or 177.0% in 2007 as compared to the prior year period. The increase was due to a \$7.2 million increase in manufacturing revenues, a \$2.0 million increase in process development services, a \$1.8 million increase in reimbursable expenses and a \$1.6 million increase in aseptic filling, partially offset by a \$0.5 million decrease in support services.

*Cost of Sales.* Cost of sales increased \$6.0 million, or 56.3% in 2007 as compared to the prior year period. The increase is due to a \$2.3 million increase in direct materials and lab supplies, a \$1.6 million increase in reimbursable expenses for specific customer materials, a \$1.6 million increase in compensation expense resulting from additional staffing requirements, and a \$0.5 million increase in other production support costs resulting from higher customer activity. Gross margins were 11.9% and (56.1)% for the nine months ended September 30, 2007 and September 30, 2006, respectively. The improvement in gross margins in 2007 as compared to the prior year period is primarily due to increased manufacturing and filling revenues and the fixed nature of certain costs.

*Selling, General and Administrative.* Selling, general and administrative expenses increased \$0.7 million, or 19.1% in 2007 as compared to the prior year period. The increase was due to a \$0.4 increase in administrative support costs and a \$0.3 million increase in compensation expense resulting from additional staffing.

*Interest, Net.* Interest expense increased \$0.3 million in 2007 as compared to the prior year period. The increase was primarily a result of higher average outstanding borrowings.

*Net Loss Before Income Taxes.* Net loss decreased \$5.1 million, or 64.8% in 2007 as compared to the prior year period. The decline in net loss was primarily attributable to margins from increased revenues.

**Table of Contents****Other Companies**

	<b>Three Months Ended September 30, 2007</b>		<b>Nine Months Ended September 30, 2007</b>	
	<b>2006</b>	<b>2006</b>	<b>2006</b>	<b>2006</b>
	<b>(In thousands)</b>			
Other income (loss), net	\$ (4,531)	\$ (235)	\$ (5,331)	\$ 385
Equity income (loss)	(4,169)	(1,910)	(9,348)	(2,180)
Net loss before income taxes	\$ (8,700)	\$ (2,145)	\$ (14,679)	\$ (1,795)

*Other Income (Loss), Net*

	<b>Three Months Ended September 30, 2007</b>		<b>Nine Months Ended September 30, 2007</b>	
	<b>2006</b>	<b>2006</b>	<b>2006</b>	<b>2006</b>
	<b>(In thousands)</b>			
Gain on sale of companies and funds, net	\$	\$	\$	\$ 1,181
Loss on trading securities		(235)		(767)
Impairment	(4,531)		(5,331)	
Other				(29)
	\$ (4,531)	\$ (235)	\$ (5,331)	\$ 385

Gain on sale of companies and funds of \$1.2 million for the nine months ended September 30, 2006 related to the sale of holdings in a cost method company whose carrying value was zero.

Loss on trading securities in 2006 primarily reflects the adjustment to fair value of our holdings in Traffic.com. We sold our holdings in Traffic.com in the fourth quarter of 2006.

We recorded impairment charges of \$4.5 million and \$0.8 million in the third and second quarters of 2007, respectively, for Ventaira. Ventaira is a cost method partner company which we determined to have experienced an other-than-temporary decline in value in accordance with our policy regarding impairment of ownership interests in and advances to companies. The Ventaira carrying value was \$0 as of September 30, 2007.

*Equity Loss.* Equity loss fluctuates with the number of partner companies accounted for under the equity method, our voting ownership percentage in these partner companies and the net results of operations of these partner companies. We recognize our share of losses to the extent we have cost basis in the equity investee or we have outstanding commitments or guarantees. Certain amounts recorded to reflect our share of the income or losses of our partner companies accounted for under the equity method are based on estimates and on unaudited results of operations of those partner companies and may require adjustments in the future when audits of these entities are made final. We report our share of the results of our equity method partner companies on a one quarter lag.

The increase in equity loss in the three and nine months ended September 30, 2007 compared to the prior year periods is primarily due to impairment charges of \$4.5 million and \$0.8 million in the third and second quarters of 2007, and an increase in the number of our equity method partner companies. During the third quarter of 2006, we acquired interests in three companies accounted for under the equity method: NuPathe, Portico and Rubicor. Since that time through September 30 2007, we acquired interests in five additional companies accounted for under the equity method: ABH, AHS, Beyond.com, Broadband National, and Cellumen. In aggregate these companies incurred losses for which we recognized our proportionate share in the three and nine months ended September 30, 2007. New holdings in growth-stage companies have led, and are expected to continue to lead to, larger equity losses until those companies reach scale and achieve profitability.



**Table of Contents****Corporate Operations**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2007</b>	<b>2006</b>	<b>2007</b>	<b>2006</b>
	<b>(In thousands)</b>			
General and administrative costs, net	\$ (5,059)	\$ (4,348)	\$ (14,704)	\$ (13,032)
Stock-based compensation	(811)	(702)	(2,905)	(2,962)
Interest income	1,763	1,309	6,023	4,346
Interest expense	(1,056)	(1,150)	(3,166)	(3,554)
Other	112	3,316	223	4,573
	<b>\$ (5,051)</b>	<b>\$ (1,575)</b>	<b>\$ (14,529)</b>	<b>\$ (10,629)</b>

*General and Administrative Costs, Net.* Our general and administrative expenses consist primarily of employee compensation, insurance, professional fees such as legal, accounting and consulting, and travel-related costs. The increase of \$0.7 million during the third quarter of 2007 as compared to the third quarter of 2006 primarily relates to an increase of \$0.1 million in employee related costs due to new hires to support Safeguard's long-term strategy and \$0.6 million of severance costs related to a former executive officer of the Company. General and administrative costs increased \$1.7 million for the nine months ended September 30, 2007, as compared to the prior year period primarily due to an increase of \$1.0 million in employee related costs due to new hires to support Safeguard's long-term strategy, an increase in professional fees of \$0.2 million, and an increase in travel and meeting expenses of \$0.5 million.

*Stock-Based Compensation.* Stock-based compensation consists primarily of expense related to stock option grants and grants of restricted stock and deferred stock units to our employees. The slight decrease for the nine months ended September 30, 2007, as compared to the prior year period is primarily attributable to lower expense related to market-based awards in 2007. Stock based compensation expense related to corporate operations is included in Selling, general and administrative in the Consolidated Statements of Operations.

*Interest Income.* Interest income includes all interest earned on available cash balances. Interest income increased \$0.5 million and \$1.7 million for the three and nine months of 2007, respectively, as compared to 2006. This net increase is attributable to higher interest rates on higher average invested cash balances in 2007 as compared to 2006.

*Interest Expense.* Interest expense is primarily related to our 2.625% convertible senior debentures with a stated maturity of 2024. Interest expense decreased for the three and nine months ended September 30, 2007 as compared to the prior year periods due to the repurchase of \$5.0 million and \$16.0 million of face value of the 2024 Debentures in the first quarter and third quarter, respectively, of 2006.

*Other.* Included in the three and nine months ended September 30, 2006 was a net gain of \$3.2 million and \$4.3 million, respectively, on the repurchase of \$21 million of face value of the 2024 Debentures.

**Income Tax Benefit**

Our consolidated net income tax benefit was \$0 and \$0.7 million for the three and nine months ended September 30, 2007, respectively, and \$0 and \$1.3 million for the three and nine months ended September 30, 2006, respectively. The tax benefits primarily related to uncertain tax positions for which the statutes of limitations expired during the periods in the applicable tax jurisdictions. We have recorded a valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit that would have been recognized in 2007 was offset by a valuation allowance.

**Liquidity and Capital Resources***Parent Company*

We fund our operations with cash on hand as well as proceeds from sales of and distributions from partner companies, private equity funds and marketable securities. In prior periods, we have also used sales of our equity and issuance of debt as sources of liquidity. Our ability to generate liquidity from sales of partner companies, sales of



marketable securities and from equity and debt issuances has been adversely affected from time to time by declines in the U.S. capital markets and other factors.

**Table of Contents**

As of September 30, 2007, at the parent company level, we had a total of \$107.5 million in cash and cash equivalents and marketable securities. We also have \$5.8 million in escrow associated with our interest payments due through March 2009 on the 2024 Debentures and our consolidated subsidiaries had cash and cash equivalents of \$4.9 million.

Proceeds from sales of and distributions from partner companies and funds were \$2.4 million in the nine months ended September 30, 2007 and \$0.7 million in the nine months ended September 30, 2006.

We maintain a revolving credit facility that provides for borrowings and issuances of letters of credit and guarantees up to \$75 million. This revolving credit facility expires June 30, 2008. Borrowing availability under the facility is reduced by the amounts outstanding for our borrowings and letters of credit and amounts guaranteed under partner company facilities maintained with that same lender. This credit facility bears interest at the prime rate (7.75% at September 30, 2007) for outstanding borrowings. The credit facility is subject to an unused commitment fee of 0.125%, which is subject to reduction based on deposits maintained at the bank. The facility requires cash collateral equal to one times our borrowings and letters of credit and amounts borrowed under the guaranteed portion of the partner company facilities maintained at the same bank.

In November 2006, we entered into an additional revolving credit facility with a separate bank that provides for borrowings and issuances of letters of credit and guarantees of up to \$20 million. Borrowing availability under the facility is reduced by the amounts outstanding for our borrowings and letters of credit and amounts guaranteed under partner company facilities maintained with that same lender. This credit facility bears interest at the prime rate for outstanding borrowings. This credit facility is subject to an unused commitment fee of 0.125%, which is subject to reduction based on deposits maintained at the bank. The facility requires cash collateral equal to one times our borrowings and letters of credit and amounts borrowed by partner companies under the guaranteed portion of the partner company facilities maintained at the same bank. As of September 30, 2007, we had no outstanding borrowings under this facility. This credit facility matures in November 2007.

Availability under our revolving credit facilities at September 30, 2007 was as follows (in thousands):

	<b>Total</b>
Size of facilities	\$ 95,000
Subsidiary facilities at same bank (a)	(40,800)
Outstanding letters of credit (b)	(6,336)
 Amount available	 \$ 47,864

(a) The amount available to borrow under the credit facilities is reduced by the amounts borrowed plus letters of credit and amounts guaranteed under partner company facilities maintained at the same

respective banks. Of the total facilities, \$32.1 million was outstanding under these facilities at September 30, 2007 and was included as debt on the Consolidated Balance Sheet.

- (b) In connection with the sale of CompuCom, we provided to the landlord of CompuCom's Dallas headquarters lease, a letter of credit, which will expire on March 19, 2019, in an amount equal to \$6.3 million.

We have committed capital of approximately \$5.4 million comprising commitments made to various private equity funds in prior years and a conditional commitment to provide a partner company with additional funding, to be funded over the next several years, including approximately \$4.6 million which is expected to be funded in the next twelve months. We do not intend to commit to new investments in additional private equity funds and may seek to further reduce our current ownership interests in, and our existing commitments to the funds in which we hold interests.

The transactions we enter into in pursuit of our strategy could increase or decrease our liquidity at any point in time. As we seek to acquire interests in technology and life sciences companies or provide additional funding to existing partner companies, we may be required to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of our interests in partner companies from time-to-time we may receive proceeds from such sales which could increase our liquidity. From time-to-time, we are engaged in discussions concerning acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps significantly.

**Table of Contents**

In May 2001, we entered into a \$26.5 million loan agreement with Warren V. Musser, our former Chairman and Chief Executive Officer. Through September 30, 2007, we have recognized net impairment charges against the loan of \$15.4 million to the estimated value of the collateral that we held at each respective date. Our efforts to collect Mr. Musser's outstanding loan obligation have included the sale of existing collateral, obtaining and selling additional collateral, litigation and negotiated resolution. Since 2001 and through September 30, 2007 we received a total of \$15.2 million in cash payments on the loan. In December 2006, we restructured the obligation to reduce the amount outstanding to \$14.8 million, bearing interest at the rate of 5% per annum, so that we could obtain new collateral, which is expected to be the primary source of repayment, along with additional collateral required to be provided to us over time. Subsequent to the restructuring of the obligation and prior to December 31, 2006, we received cash of approximately \$1.0 million from the sale of collateral. The carrying value of the loan at September 30, 2007 and December 31, 2006 was zero. Cash payments, when received, are recognized as Recovery-related party in our Consolidated Statements of Operations.

We have received distributions as both a general partner and a limited partner from certain private equity funds. Under certain circumstances, we may be required to return a portion or all the distributions we received as a general partner (the "clawback"). The clawback liability is joint and several, such that we may be required to fund the clawback for other general partners should they default. The funds have taken several steps to reduce the potential liabilities should other general partners default, including withholding all general partner distributions in escrow and adding rights of set-off among certain funds. We believe our liability due to the default of other general partners is remote. Assuming the private equity funds in which we are a general partner are liquidated or dissolved on September 30, 2007 and assuming for these purposes the only distributions from the funds were equal to the carrying value of the funds on the September 30, 2007 financial statements, the maximum clawback we would be required to return for our general partner interest is approximately \$8 million. As of September 30, 2007 management estimated this liability to be approximately \$6.7 million, of which \$5.3 million was reflected in accrued expenses and other current liabilities and \$1.4 million was reflected in other long-term liabilities on the Consolidated Balance Sheets.

We have outstanding \$129 million of 2.625% convertible senior debentures with a stated maturity of March 15, 2024. Interest on the 2024 Debentures is payable semi-annually. At the note holders' option, the notes are convertible into our common stock before the close of business on March 14, 2024 subject to certain conditions. The conversion rate of the notes is \$7.2174 of principal amount per share. The closing price of our common stock on September 28, 2007 was \$2.29. The note holders may require repurchase of the 2024 Debentures on March 21, 2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective amount plus accrued and unpaid interest. The note holders may also require repurchase of the 2024 Debentures upon certain events, including sale of all or substantially all of our common stock or assets, liquidation, dissolution or a change in control. Subject to certain conditions, we may redeem all or some of the 2024 Debentures commencing March 20, 2009. During 2006, we repurchased \$21 million of face value of the 2024 Debentures for \$16.4 million in cash.

For the reasons we have discussed, we believe our cash and cash equivalents at September 30, 2007 and other internal sources of cash flow are expected to be sufficient to fund our cash requirements for at least the next twelve months, including commitments to our existing companies and funds, our current operating plan to acquire interests in new partner companies and our general corporate requirements.

***Consolidated Partner Companies***

Most of our consolidated partner companies incurred losses in 2006 and the three and nine months ended September 30, 2007 and may need additional capital to fund their operations. From time-to-time, some or all of our consolidated subsidiaries may require additional debt or equity financing or credit support from us to fund planned expansion activities. If we decide not to provide sufficient capital resources to allow them to reach a positive cash flow position, and they are unable to raise capital from outside resources, they may need to scale back their operations. If Alliance Consulting meets its business plan for the remainder of 2007 and the related milestones established by us, we believe it will have sufficient cash or availability under established lines of credit, as amended, to fund its operations through 2007. We expect Acsis and Clariant will require additional capital during the remainder of 2007 to fund their business plans, and we believe that Laureate Pharma may need additional capital during the remainder of 2007. On March 7, 2007, we provided a subordinated revolving credit line (the "Mezzanine Facility") to

Clariant. Under the Mezzanine Facility, which expires December 8, 2008, we committed to provide Clariant access to up to \$6 million in working capital funding. Amounts funded under the Mezzanine Facility will earn interest at an annual rate of 12%. The Mezzanine Facility was originally \$12 million, but was reduced by \$6 million as a result of the ACIS Sale.

**Table of Contents**

Alliance Consulting, Clariant and Laureate Pharma maintain credit facilities with one of our lenders. Borrowings are secured by substantially all of the assets of the respective subsidiaries. These obligations bear interest at variable rates ranging between the prime rate minus 0.5% and the prime rate plus 0.5%. These facilities contain financial and non-financial covenants. During the three months ended September 30, 2007, Alliance Consulting and Clariant each did not comply with certain of their financial covenants under their respective facilities and subsequently received waivers from the lender, regarding such non-compliance. In addition, Clariant entered into an amendment with the lender to modify its financial covenant requirements on a prospective basis.

As of September 30, 2007, outstanding borrowings by consolidated partner companies under guaranteed facilities were \$32.1 million.

In July 2007, Acsis amended and restated its credit facility with its bank, providing up to \$4.5 million of availability, subject to a borrowing base calculation. The facility expires in July 2008 and bears interest at rates ranging from the prime rate plus 1.5% to the prime rate plus 2.25% depending on Acsis liquidity. In September 2007, the Company serviced \$1.5 million of Acsis bank debt in exchange for a \$1.5 million promissory note from Acsis.

In September 2006, Clariant entered into a \$5 million senior secured revolving credit agreement. Borrowing availability under the agreement is based on the level of Clariant's qualified accounts receivable, less certain reserves. The agreement has a two-year term and bears interest at variable rates based on the lower of LIBOR plus 3.25% or the prime rate plus 0.5%. As of September 30, 2007, Clariant had \$4.1 million outstanding borrowings under this facility and had no availability based on the level of qualified accounts receivable. During the three months ended September 30, 2007 Clariant did not comply with certain of its financial covenants under this facility and subsequently received a waiver from the lender, regarding such non-compliance. In addition, Clariant entered into an amendment with the lender to modify its financial covenant requirements on a prospective basis.

***Analysis of Parent Company Cash Flows***

Cash flow activity for the Parent Company was as follows:

	<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>	
Net cash used in operating activities	\$ (13,214)	\$ (9,076)
Net cash provided by (used in) investing activities	59,612	(43,169)
Net cash provided by (used in) financing activities	586	(18,011)
	<b>\$ 46,984</b>	<b>\$ (70,256)</b>

***Cash Used In Operating Activities***

Net cash used in operating activities increased \$4.1 million in 2007 as compared to the prior year period. The increase was primarily attributable to higher operating costs and corporate severance payments as compared to the prior year period.

***Cash Provided by (Used In) Investing Activities***

Net cash provided by investing activities increased \$102.8 million in 2007 as compared to the prior year period. This increase was primarily attributable to a \$91.3 million net decrease in marketable securities and a \$19.7 million net increase from the proceeds from sale of discontinued operations in 2007 as compared to the prior year period. Partially offsetting the overall increase was a \$7.2 million net increase in cash used for acquisitions of ownership interests in companies and funds, net of cash acquired.

***Cash Provided by (Used In) Financing Activities***

Net cash provided by (used in) financing activities increased \$18.6 million in 2007 as compared to the prior year period. The increase was primarily related to \$16.2 million of cash used to repurchase \$21 million of face value of the 2024 Debentures and repayment of advances from subsidiaries of \$3.3 million in the prior year period.



**Table of Contents****Consolidated Working Capital**

Consolidated working capital decreased to \$75.3 million at September 30, 2007 compared to \$137.0 million at December 31, 2006. The decrease is primarily attributable to cash expended on new and follow-on holdings as well as to fund continuing operations.

**Analysis of Consolidated Company Cash Flows**

Cash flow activity was as follows:

	<b>Nine Months Ended September 30,</b>	
	<b>2007</b>	<b>2006</b>
	<b>(in thousands)</b>	
Net cash used in operating activities	\$ (32,153)	\$ (17,891)
Net cash provided by (used in) investing activities	62,113	(50,510)
Net cash provided by (used in) financing activities	16,169	(5,004)
	\$ 46,129	\$ (73,405)

**Cash Used in Operating Activities**

Net cash used in operating activities increased \$14.3 million in 2007 as compared to the prior year period. The increase was primarily related to an increase in net loss, offset by working capital changes in 2007 as compared to the prior year period.

**Cash Provided by (Used In) Investing Activities**

Net cash provided by (used in) investing activities increased \$112.6 million in 2007 as compared to the prior year period. This increase was primarily related to a net increase of \$23.8 million of proceeds from the sale of discontinued operations and a net decrease of \$91.3 million in marketable securities. Partially offsetting the overall increase was a net increase of \$12.5 million in cash used for acquisitions of ownership interests in companies and funds, net of cash acquired in 2007 as compared to the prior year period.

**Cash Provided by (Used In) Financing Activities**

Net cash provided by financing activities increased \$21.2 million in 2007 as compared to the prior year period. The increase was primarily related to an increase in net borrowings under credit facilities and term debt in 2007 and a decrease of \$16.4 million of cash used to repurchase \$21 million of face value of the 2024 Debentures in 2006.

**Contractual Cash Obligations and Other Commercial Commitments**

The following table summarizes our contractual obligations and other commercial commitments as of September 30, 2007 by period due or expiration of the commitment.

	<b>Total</b>	<b>Payments Due by Period</b>			<b>Due after 2011</b>
		<b>Rest of 2007</b>	<b>2008 and 2009</b>	<b>2010 and 2011</b>	
	<b>(in millions)</b>				
Contractual Cash Obligations					
Lines of credit (a)	\$ 39.4	\$ 1.4	\$ 38.0	\$	\$
Long-term debt (a)	5.6	0.5	3.9	1.2	
Capital leases	2.8	0.5	2.3		
Convertible senior debentures (b)	129.0				129.0
Operating leases	25.7	1.3	7.7	5.1	11.6
Funding commitments (c)	5.4	3.6	1.8		
Potential clawback liabilities (d)	6.7		6.7		
Other long-term obligations (e)	2.8	0.1	1.2	1.4	0.1



Total Contractual Cash Obligations	\$ 217.4	\$ 7.4	\$ 61.6	\$ 7.7	\$ 140.7
------------------------------------	----------	--------	---------	--------	----------

42

---

**Table of Contents**

	<b>Amount of Commitment Expiration by Period</b>				
	<b>Total</b>	<b>Rest of 2007</b>	<b>2008 and 2009 (in millions)</b>	<b>2010 and 2011</b>	<b>Due after 2011</b>
Other Commitments					
Letters of credit (f)	\$ 9.4	\$ 0.1	\$ 3.0	\$	\$ 6.3

(a) We have various forms of debt including lines of credit, term loans and equipment leases. Of our total outstanding guarantees of \$49.3 million, \$32.1 million of outstanding debt associated with the guarantees was included on the Consolidated Balance Sheet at September 30, 2007. The remaining \$17.2 million was not reflected on the Consolidated Balance Sheet or in the above table.

(b) In February 2004, we completed the issuance of \$150 million of the 2024 Debentures with a stated maturity of March 15, 2024. During

2006, we repurchased \$21 million of the face value of the 2024 Debentures for \$16.4 million in cash. The 2024 Debenture holders may require us to repurchase the 2024 Debentures on March 21, 2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective face amount plus accrued and unpaid interest.

- (c) These amounts include funding commitments to private equity funds and private companies. The amounts have been included in the respective years based on estimated timing of capital calls provided to us by the funds management. Also included is our \$3.0 million conditional commitment to provide a partner company with additional funding.

(d) We have received distributions as both a general partner and a limited partner from certain private equity funds. Under certain circumstances, we may be required to return a portion or all the distributions we received as a general partner to the fund for a further distribution to the fund's limited partners (the clawback ). Assuming the funds were liquidated or dissolved on September 30, 2007 and the only value provided by the funds was the carrying values represented on the September 30, 2007 financial statements, the maximum clawback we would be required to return is \$8 million. As of September 30, 2007, management estimated its liability to be

approximately \$6.7 million, of which \$5.3 million was reflected in accrued expenses and other current liabilities and \$1.4 million was reflected in other long-term liabilities on the Consolidated Balance Sheets.

- (e) Reflects the amount payable to our former Chairman and CEO under a consulting contract.
- (f) Letters of credit include a \$6.3 million letter of credit provided to the landlord of CompuCom's Dallas headquarters lease in connection with the sale of CompuCom and \$3.1 million of letters of credit issued by or on behalf of partner companies supporting their office leases.

We have retention employment agreements with certain executive officers that provide for severance payments to the executive officer in the event the officer is terminated without cause or the officer terminates their employment for good reason.

We are involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the consolidated financial position or results of operations.

***Recent Accounting Pronouncements***

See Note 6 to the Consolidated Financial Statements.

**Factors That May Affect Future Results**

You should carefully consider the information set forth below before making an investment decision. If any of the following risks actually occur, our business, financial condition or results of operations could be materially harmed, and the

**Table of Contents**

value of our securities may decline. You should also refer to other information included or incorporated by reference in this report.

**Risks Related to Our Business**

***Our business depends upon the performance of our partner companies, which is uncertain.***

If our partner companies do not succeed, the value of our assets could be significantly reduced and require substantial impairments or write-offs, and our results of operations and the price of our common stock could decline. The risks relating to our partner companies include:

- § most of our partner companies have a history of operating losses or a limited operating history;
- § intensifying competition affecting the products and services our partner companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth;
- § inability to adapt to the rapidly changing marketplaces;
- § inability to manage growth;
- § the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all;
- § inability to protect their proprietary rights and infringing on the proprietary rights of others;
- § certain of our partner companies could face legal liabilities from claims made against their operations, products or work;
- § the impact of economic downturns on their operations, results and growth prospects;
- § inability to attract and retain qualified personnel; and
- § government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies.

These risks are discussed in greater detail under the caption **Risks Related to Our Partner Companies** below. ***The identity of our partner companies and the nature of our interests in them could vary widely from period to period.***

As part of our strategy, we continually assess the value to our shareholders of our interests in our partner companies. We also regularly evaluate alternative uses for our capital resources. As a result, depending on market conditions, growth prospects and other key factors, we may at any time:

- § change the partner companies on which we focus;
- § sell some or all of our interests in any of our partner companies;
- § or otherwise change the nature of our interests in our partner companies. Therefore, the nature of our holdings could vary significantly from period to period.

Our consolidated financial results may also vary significantly based upon the partner companies that are included in our financial statements. For example:

- § For the three and nine months ended September 30, 2007, we consolidated the results of operations of Acsis, Alliance Consulting, Clariant and Laureate Pharma.
- § In March 2007, we completed the sale of Pacific Title and its results of operations for the periods prior to the sale are presented as discontinued operations in the consolidated financial statements.





**Table of Contents**

***Our partner companies currently provide us with little cash flow from their operations so we rely on cash on hand, liquidity events and our ability to generate cash from capital raising activities to finance our operations.***

We need capital to acquire new partner companies and to fund the capital needs of our existing partner companies. We also need cash to service and repay our outstanding debt, finance our corporate overhead and meet our funding commitments to private equity funds. As a result, we have substantial cash requirements. Our partner companies currently provide us with little cash flow from their operations. To the extent our partner companies generate any cash from operations, they generally retain the funds to develop their own businesses. As a result, we must rely on cash on hand, liquidity events and new capital raising activities to meet our cash needs. If we are unable to find ways of monetizing our holdings or to raise additional capital on attractive terms, we may face liquidity issues that will require us to curtail our new business efforts, constrain our ability to execute our business strategy and limit our ability to provide financial support to our existing partner companies.

***Fluctuations in the price of the common stock of our publicly-traded holdings may affect the price of our common stock.***

Fluctuations in the market prices of the common stock of our publicly-traded holdings are likely to affect the price of our common stock. The market prices of our publicly-traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance. For example, the aggregate market value of our holdings in Clariant (Nasdaq: CLRT) at September 30, 2007 was approximately \$88.9 million and at December 31, 2006 was approximately \$72.8 million.

***Intense competition from other acquirers of interests in companies could result in lower gains or possibly losses on our partner companies.***

We face intense competition from other capital providers as we acquire and develop interests in our partner companies. Some of our competitors have more experience identifying and acquiring companies and have greater financial and management resources, brand name recognition or industry contacts than we have. Despite making most of our acquisitions at a stage when our partner companies are not publicly traded, we may still pay higher prices for those equity interests because of higher valuations of similar public companies and competition from other acquirers and capital providers, which could result in lower gains or possibly losses.

***We may be unable to obtain maximum value for our holdings or sell our holdings on a timely basis.***

We hold significant positions in our partner companies. Consequently, if we were to divest all or part of our holdings in a partner company, we may have to sell our interests at a relative discount to a price which may be received by a seller of a smaller portion. For partner companies with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices. The trading volume and public float in the common stock of our publicly-traded partner companies are small relative to our holdings. As a result, any significant divestiture by us of our holdings in these partner companies would likely have a material adverse effect on the market price of their common stock and on our proceeds from such a divestiture. Additionally, we may not be able to take our partner companies public as a means of monetizing our position or creating shareholder value.

Registration and other requirements under applicable securities laws may adversely affect our ability to dispose of our holdings on a timely basis.

***Our success is dependent on our executive management.***

Our success is dependent on our executive management team's ability to execute our strategy. A loss of one or more of the members of our executive management team without adequate replacement could have a material adverse effect on us.

***Our business strategy may not be successful if valuations in the market sectors in which our partner companies participate decline.***

Our strategy involves creating value for our shareholders by helping our partner companies build value and, if appropriate, accessing the public and private capital markets. Therefore, our success is dependent on the value of our partner companies as determined by the public and private capital markets. Many factors, including reduced market interest, may cause the market value of our publicly traded partner companies to decline. If valuations in the market sectors in which our

**Table of Contents**

partner companies participate decline, their access to the public and private capital markets on terms acceptable to them may be limited.

***Our partner companies could make business decisions that are not in our best interests or with which we do not agree, which could impair the value of our holdings.***

Although we may seek a controlling equity interest and participation in the management of our partner companies, we may not be able to control the significant business decisions of our partner companies. We may have shared control or no control over some of our partner companies. In addition, although we currently own a controlling interest in some of our partner companies, we may not maintain this controlling interest. Acquisitions of interests in partner companies in which we share or have no control, and the dilution of our interests in or loss of control of partner companies, will involve additional risks that could cause the performance of our interests and our operating results to suffer, including:

§ the management of a partner company having economic or business interests or objectives that are different from, ours; and

§ partner companies not taking our advice with respect to the financial or operating difficulties they may encounter.

Our inability to adequately control our partner companies also could prevent us from assisting them, financially or otherwise, or could prevent us from liquidating our interests in them at a time or at a price that is favorable to us. Additionally, our partner companies may not act in ways that are consistent with our business strategy. These factors could hamper our ability to maximize returns on our interests and cause us to recognize losses on our interests in these partner companies.

***We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to avoid registration under the Investment Company Act.***

The Investment Company Act of 1940 regulates companies which are engaged primarily in the business of investing, reinvesting, owning, holding or trading in securities. Under the Investment Company Act, a company may be deemed to be an investment company if it owns investment securities with a value exceeding 40% of the value of its total assets (excluding government securities and cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to this test as the 40% Test. We are a company that partners with growth-stage technology and life sciences companies to build value; we are not engaged primarily in the business of investing, reinvesting or trading in securities. We are in compliance with the 40% Test. Consequently, we do not believe that we are an investment company under the Investment Company Act.

We monitor our compliance with the 40% Test and seek to conduct our business activities to comply with this test. It is not feasible for us to be regulated as an investment company because the Investment Company Act rules are inconsistent with our strategy of actively helping our partner companies in their efforts to build value. In order to continue to comply with the 40% Test, we may need to take various actions which we would otherwise not pursue. For example, we may need to retain a majority interest in a partner company that we no longer consider strategic, we may not be able to acquire an interest in a company unless we are able to obtain majority ownership interest in the company, or we may be limited in the manner or timing in which we sell our interests in a partner company. Our ownership levels may also be affected if our partner companies are acquired by third parties or if our partner companies issue stock which dilutes our majority ownership. The actions we may need to take to address these issues while maintaining compliance with the 40% Test could adversely affect our ability to create and realize value at our partner companies.

**Risks Related to Our Partner Companies**

***Most of our partner companies have a history of operating losses or limited operating history and may never be profitable.***

Most of our partner companies have a history of operating losses or limited operating history, have significant historical losses and may never be profitable. Many have incurred substantial costs to develop and market their products, have incurred net losses and cannot fund their cash needs from operations. We expect that the operating expenses of certain of our partner companies will increase substantially in the foreseeable future as they continue to develop products and services, increase sales and marketing efforts and expand operations.



**Table of Contents**

***Our partner companies face intense competition, which could adversely affect their business, financial condition, results of operations and prospects for growth.***

There is intense competition in the technology and life sciences marketplaces, and we expect competition to intensify in the future. Our business, financial condition, results of operations and prospects for growth will be materially adversely affected if our partner companies are not able to compete successfully. Many of the present and potential competitors may have greater financial, technical, marketing and other resources than those of our partner companies. This may place our partner companies at a disadvantage in responding to the offerings of their competitors, technological changes or changes in client requirements. Also, our partner companies may be at a competitive disadvantage because many of their competitors have greater name recognition, more extensive client bases and a broader range of product offerings. In addition, our partner companies may compete against one another.

***Our partner companies may fail if they do not adapt to the rapidly changing technology and life sciences marketplaces.***

If our partner companies fail to adapt to rapid changes in technology and customer and supplier demands, they may not become or remain profitable. There is no assurance that the products and services of our partner companies will achieve or maintain market penetration or commercial success, or that the businesses of our partner companies will be successful.

The technology and life sciences marketplaces are characterized by:

- § rapidly changing technology;
- § evolving industry standards;
- § frequent new products and services;
- § shifting distribution channels;
- § evolving government regulation;
- § frequently changing intellectual property landscapes; and
- § changing customer demands.

Our future success will depend on our partner companies' ability to adapt to this rapidly evolving marketplace. They may not be able to adequately or economically adapt their products and services, develop new products and services or establish and maintain effective distribution channels for their products and services. If our partner companies are unable to offer competitive products and services or maintain effective distribution channels, they will sell fewer products and services and forego potential revenue, possibly causing them to lose money. In addition, we and our partner companies may not be able to respond to the rapid technology changes in an economically efficient manner, and our partner companies may become or remain unprofitable.

***Many of our partner companies may grow rapidly and may be unable to manage their growth.***

We expect some of our partner companies to grow rapidly. Rapid growth often places considerable operational, managerial and financial strain on a business. To successfully manage rapid growth, our partner companies must, among other things:

- § rapidly improve, upgrade and expand their business infrastructures;
- § scale-up production operations;
- § develop appropriate financial reporting controls;
- § attract and maintain qualified personnel; and

§ maintain appropriate levels of liquidity.

If our partner companies are unable to manage their growth successfully, their ability to respond effectively to competition and to achieve or maintain profitability will be adversely affected.

**Table of Contents**

***Our partner companies may need to raise additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all.***

Our partner companies may need to raise additional funds in the future and we cannot be certain that they will be able to obtain additional financing on favorable terms, if at all. Because our resources and our ability to raise capital are limited, we may not be able to provide our partner companies with sufficient capital resources to enable them to reach a cash flow positive position. If our partner companies need to, but are not able to raise capital from other outside sources, then they may need to cease or scale back operations.

***Some of our partner companies may be unable to protect their proprietary rights and may infringe on the proprietary rights of others.***

Our partner companies assert various forms of intellectual property protection. Intellectual property may constitute an important part of our partner companies' assets and competitive strengths. Federal law, most typically, copyright, patent, trademark and trade secret laws, generally protects intellectual property rights. Although we expect that our partner companies will take reasonable efforts to protect the rights to their intellectual property, the complexity of international trade secret, copyright, trademark and patent law, coupled with the limited resources of these partner companies and the demands of quick delivery of products and services to market, create a risk that their efforts will prove inadequate to prevent misappropriation of our partner companies' technology, or third parties may develop similar technology independently.

Some of our partner companies also license intellectual property from third parties and it is possible that they could become subject to infringement actions based upon their use of the intellectual property licensed from those third parties. Our partner companies generally obtain representations as to the origin and ownership of such licensed intellectual property; however, this may not adequately protect them. Any claims against our partner companies' proprietary rights, with or without merit, could subject our partner companies to costly litigation and the diversion of their technical and management personnel from other business concerns. If our partner companies incur costly litigation and their personnel are not effectively deployed, the expenses and losses incurred by our partner companies will increase and their profits, if any, will decrease.

Third parties have and may assert infringement or other intellectual property claims against our partner companies based on their patents or other intellectual property claims. Even though we believe our partner companies' products do not infringe any third party's patents, they may have to pay substantial damages, possibly including treble damages, if it is ultimately determined that they do. They may have to obtain a license to sell their products if it is determined that their products infringe another person's intellectual property. Our partner companies might be prohibited from selling their products before they obtain a license, which, if available at all, may require them to pay substantial royalties. Even if infringement claims against our partner companies are without merit, defending these types of lawsuits take significant time, may be expensive and may divert management attention from other business concerns.

***Certain of our partner companies could face legal liabilities from claims made against their operations, products or work.***

The manufacture and sale of certain of our partner companies' products entails an inherent risk of product liability. Certain of our partner companies maintain product liability insurance. Although none of our partner companies to date have experienced any material losses, there can be no assurance that they will be able to maintain or acquire adequate product liability insurance in the future and any product liability claim could have a material adverse effect on our partner companies' revenues and income. In addition, many of the engagements of our partner companies involve projects that are critical to the operation of their clients' businesses. If our partner companies fail to meet their contractual obligations, they could be subject to legal liability, which could adversely affect their business, operating results and financial condition. The provisions our partner companies typically include in their contracts, which are designed to limit their exposure to legal claims relating to their services and the applications they develop, may not protect our partner companies or may not be enforceable. Also as consultants, some of our partner companies depend on their relationships with their clients and their reputation for high quality services and integrity to retain and attract clients. As a result, claims made against our partner companies' work may damage their reputation, which in turn, could impact their ability to compete for new work and negatively impact their revenues and profitability.

***Our partner companies success depends on their ability to attract and retain qualified personnel.***

Our partner companies are dependent upon their ability to attract and retain senior management and key personnel, including trained technical and marketing personnel. Our partner companies will also need to continue to hire additional

**Table of Contents**

personnel as they expand. A shortage in the availability of the requisite qualified personnel would limit the ability of our partner companies to grow, to increase sales of their existing products and services and to launch new products and services.

***Government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies.***

Failure to comply with applicable requirements of the FDA or comparable regulation in foreign countries can result in fines, recall or seizure of products, total or partial suspension of production, withdrawal of existing product approvals or clearances, refusal to approve or clear new applications or notices and criminal prosecution. Manufacturers of pharmaceuticals and medical diagnostic devices and operators of laboratory facilities are subject to strict federal and state regulation regarding validation and the quality of manufacturing and laboratory facilities. Failure to comply with these quality regulation systems requirements could result in civil or criminal penalties or enforcement proceedings, including the recall of a product or a cease distribution order. The enactment of any additional laws or regulations that affect healthcare insurance policy and reimbursement (including Medicare reimbursement) could negatively affect our partner companies. If Medicare or private payors change the rates at which our partner companies or their customers are reimbursed by insurance providers for their products, such changes could adversely impact our partner companies.

***Some of our partner companies are subject to significant environmental, health and safety regulation.***

Some of our partner companies are subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials as well as to the safety and health of manufacturing and laboratory employees. In addition, the federal Occupational Safety and Health Administration has established extensive requirements relating to workplace safety.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to equity price risks on the marketable portion of our securities. These securities include an equity position in one public partner company, Clariant, which has experienced significant volatility in its stock price. Historically, we have not attempted to reduce or eliminate our market exposure on securities. Based on closing market prices at September 30, 2007, the fair market value of our holdings in public securities was approximately \$88.9 million. A 20% decrease in equity prices would result in an approximate \$17.8 million decrease in the fair value of our publicly traded securities.

In February 2004, we completed the issuance of \$150 million of fixed rate notes with a stated maturity of March 2024. Interest payments of approximately \$1.7 million are due March and September of each year. The holders of the 2024 Debentures may require repurchase of the notes on March 21, 2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective amount plus accrued and unpaid interest. On October 8, 2004, we utilized approximately \$16.7 million of the proceeds from the CompuCom sale to escrow interest payments due through March 15, 2009. During 2006, the Company repurchased \$21.0 million of the face value of the 2024 Debentures for \$16.4 million in cash.

	Remainder of			After	Fair Market Value at
	2007	2008	2009	2009	September 30, 2007
Liabilities					
Convertible Senior Notes due by year (in millions)				\$ 129.0	\$ 109.4
Fixed Interest Rate	2.625%	2.625%	2.625%	2.625%	N/A
Interest Expense (in millions)	\$ 0.8	\$ 3.4	\$ 3.4	\$ 48.1	N/A

**Item 4. Controls and Procedures**



Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow

**Table of Contents**

timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Our business strategy involves the acquisition of new businesses on an on-going basis, most of which are young, growing companies. Typically, these companies have not historically had all of the controls and procedures they would need to comply with the requirements of the Securities Exchange Act of 1934 and the rules promulgated thereunder. These companies also frequently develop new products and services. Following an acquisition, or the launch of a new product or service, we work with the company's management to implement all necessary controls and procedures.

**Table of Contents**

**PART II**  
**OTHER INFORMATION**

**Item 1. Legal Proceedings**

In anticipation of the sale of Pacific Title in the first quarter of 2007, the Company permitted the employment agreement of the Pacific Title CEO to expire without renewal, and thereby his employment ceased. Following the sale, the former CEO's counsel demanded payment of severance benefits under his employment agreement, as well as payment of his deferred stock units and other amounts substantially in excess of the maximum amounts the Company believed were arguably due. The former CEO and the Company thereafter engaged in negotiations, but were ultimately unable to settle on the appropriate amounts due. On or about August 13, 2007, the former CEO filed a complaint in the Superior Court of the State of California, County of Los Angeles, Central District, against the Company and Pacific Title, alleging, among other things: wrongful termination, conversion, unfair competition, violation of the labor code, breach of contract and negligence. In his complaint, the former CEO makes claims for compensatory damages in excess of \$18 million, plus exemplary and punitive damages and interest. While the Company does not dispute that certain amounts may be due the former CEO under various agreements, the Company and Pacific Title deny the majority of the claims under his complaint and the amounts claimed and intend to vigorously defend against such claims. The Company has engaged counsel to represent the Company and Pacific Title in this matter, and have also put the Company's insurance carriers on notice of the claims. Counsel has answered the complaint and has filed a cross-complaint on the Company's and Pacific Title's behalf. The answer denied the relief sought and the Cross Complaint alleged breach of fiduciary duty and breach of contract. The case is proceeding through the discovery phase. It is the Company's belief that amounts presently reserved in its financial statements in connection with this matter are sufficient to cover any amounts ultimately due under the various agreements that existed between the former CEO and Pacific Title and the Company.

**Item 1A. Risk Factors**

Except as set forth below, there have been no material changes in our risk factors from the information set forth above under the heading "Factors That May Affect Future Results" and in our Annual Report on Form 10-K for the year ended December 31, 2006.

***The identity of our partner companies and the nature of our interests in them could vary widely from period to period.***

As part of our strategy, we continually assess the value to our shareholders of our interests in our partner companies. We also regularly evaluate alternative uses for our capital resources. As a result, depending on market conditions, growth prospects and other key factors, we may, at any time, change the partner companies on which we focus, sell some or all of our interests in any of our partner companies or otherwise change the nature of our interests in our partner companies. Therefore, the nature of our holdings in them could vary significantly from period to period.

Our consolidated financial results may also vary significantly based upon the partner companies that are included in our financial statements. For example:

§ For the three and nine months ended September 30, 2007, we consolidated the results of operations of Acsis, Alliance Consulting, Clariant and Laureate Pharma.

§ In March 2007, we completed the sale of Pacific Title and its results of operations for the periods prior to the sale are presented as discontinued operations in the consolidated financial statements.

***Fluctuations in the price of the common stock of our publicly-traded holdings may affect the price of our common stock.***

Fluctuations in the market prices of the common stock of our publicly-traded holdings are likely to affect the price of our common stock. The market prices of our publicly-traded holdings have been highly volatile and subject to fluctuations unrelated or disproportionate to operating performance. For example, the aggregate market value of our holdings in Clariant (Nasdaq: CLRT) at September 30, 2007 was approximately \$88.9 million, and at December 31, 2006 was approximately \$72.8 million.

**Table of Contents**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2006, which could materially affect our business, financial condition or future results. The risks described in this report and in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

**Table of Contents****Item 6. Exhibits**

(a) Exhibits.

The following is a list of exhibits required by Item 601 of Regulation S-K filed as part of this Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. The exhibit table below includes the Form Type and Filing Date of the previous filing and the location of the exhibit in the previous filing which is being incorporated by reference herein. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in a footnote to this table.

<b>Exhibit Number</b>	<b>Description</b>	<b>Incorporated Filing Reference</b>	
		<b>Form Type &amp; Filing Date</b>	<b>Original Exhibit Number</b>
3.1	Second Amended and Restated Articles of Incorporation	Form 8-K 10/24/07	3.1
3.2	Amended and Restated Bylaws	Form 8-K 10/24/07	3.2
10.1. *	Letter Agreement by and between Safeguard Scientifics, Inc. and Steven J. Feder dated August 16, 2007	Form 8-K  8/20/07	99.1
10.2 *	Letter Agreement by and between Safeguard Scientifics, Inc. and Brian J. Sisko dated August 20, 2007		
10.3 *	Stock Option Grant Certificates issued to Brian J. Sisko dated August 20, 2007		
31.1	Certification of Peter J. Boni pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934		
31.2	Certification of Raymond J. Land pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934		
32.1	Certification of Peter J. Boni pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.		
32.2	Certification of Raymond J. Land pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.		

Filed herewith

\* Management contracts or compensatory plans, contracts or arrangements in which directors and/or executive officers of the

Registrant may  
participate.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SAFEGUARD SCIENTIFICS, INC.

Date: November 5, 2007

PETER J. BONI

Peter J. Boni  
*President and Chief Executive Officer*

Date: November 5, 2007

RAYMOND J. LAND

Raymond J. Land  
*Senior Vice President and Chief Financial Officer*

54